PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35242278-0	2022	Diosmetin Protects against Cardiac Hypertrophy via p62/Keap1/Nrf2 Signaling Pathway.	diosmetin	0-9	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	51-54
35242278-0	2022	Diosmetin Protects against Cardiac Hypertrophy via p62/Keap1/Nrf2 Signaling Pathway.	diosmetin	0-9	Kelch-like ECH-associated protein 1	Rattus norvegicus	55-60
35242278-0	2022	Diosmetin Protects against Cardiac Hypertrophy via p62/Keap1/Nrf2 Signaling Pathway.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	61-65
35242278-6	2022	Mechanistically, diosmetin inhibited autophagy by activating the PI3K/Akt pathway.	diosmetin	17-26	AKT serine/threonine kinase 1	Rattus norvegicus	70-73
35242278-7	2022	In particular, diosmetin induced the accumulation of p62 and its interaction with Keap1, promoted the nuclear translocation of Nrf2, and increased the expression of antioxidant stress genes in the process of cardiac hypertrophy.	diosmetin	15-24	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	53-56
35242278-7	2022	In particular, diosmetin induced the accumulation of p62 and its interaction with Keap1, promoted the nuclear translocation of Nrf2, and increased the expression of antioxidant stress genes in the process of cardiac hypertrophy.	diosmetin	15-24	Kelch-like ECH-associated protein 1	Rattus norvegicus	82-87
35242278-7	2022	In particular, diosmetin induced the accumulation of p62 and its interaction with Keap1, promoted the nuclear translocation of Nrf2, and increased the expression of antioxidant stress genes in the process of cardiac hypertrophy.	diosmetin	15-24	NFE2 like bZIP transcription factor 2	Rattus norvegicus	127-131
35242278-8	2022	Furthermore, knockdown of p62 in rat primary cardiomyocytes abrogate the protective effect of diosmetin on cardiomyocyte hypertrophy.	diosmetin	94-103	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	26-29
35242278-9	2022	Similarly, the Nrf2 inhibitor ML385 obviously abolished the above effects by diosmetin treatment.	diosmetin	77-86	NFE2 like bZIP transcription factor 2	Rattus norvegicus	15-19
35242278-10	2022	In conclusion, our results suggest that diosmetin protects cardiac hypertrophy under pressure overload through the p62/Keap1/Nrf2 signaling pathway, suggesting the potential of diosmetin as a novel therapy for pathological cardiac hypertrophy.	diosmetin	40-49	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	115-118
35242278-10	2022	In conclusion, our results suggest that diosmetin protects cardiac hypertrophy under pressure overload through the p62/Keap1/Nrf2 signaling pathway, suggesting the potential of diosmetin as a novel therapy for pathological cardiac hypertrophy.	diosmetin	40-49	Kelch-like ECH-associated protein 1	Rattus norvegicus	119-124
35242278-10	2022	In conclusion, our results suggest that diosmetin protects cardiac hypertrophy under pressure overload through the p62/Keap1/Nrf2 signaling pathway, suggesting the potential of diosmetin as a novel therapy for pathological cardiac hypertrophy.	diosmetin	40-49	NFE2 like bZIP transcription factor 2	Rattus norvegicus	125-129
35242278-10	2022	In conclusion, our results suggest that diosmetin protects cardiac hypertrophy under pressure overload through the p62/Keap1/Nrf2 signaling pathway, suggesting the potential of diosmetin as a novel therapy for pathological cardiac hypertrophy.	diosmetin	177-186	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	115-118
35242278-10	2022	In conclusion, our results suggest that diosmetin protects cardiac hypertrophy under pressure overload through the p62/Keap1/Nrf2 signaling pathway, suggesting the potential of diosmetin as a novel therapy for pathological cardiac hypertrophy.	diosmetin	177-186	Kelch-like ECH-associated protein 1	Rattus norvegicus	119-124
35242278-10	2022	In conclusion, our results suggest that diosmetin protects cardiac hypertrophy under pressure overload through the p62/Keap1/Nrf2 signaling pathway, suggesting the potential of diosmetin as a novel therapy for pathological cardiac hypertrophy.	diosmetin	177-186	NFE2 like bZIP transcription factor 2	Rattus norvegicus	125-129
33751333-0	2021	Diosmetin, a novel transient receptor potential vanilloid 1 antagonist, alleviates the UVB radiation-induced skin inflammation in mice.	diosmetin	0-9	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	19-59
34881386-0	2022	Diosmetin alleviated cerebral ischemia/reperfusion injury in vivo and in vitro by inhibiting oxidative stress via the SIRT1/Nrf2 signaling pathway.	diosmetin	0-9	sirtuin 1	Rattus norvegicus	118-123
34881386-0	2022	Diosmetin alleviated cerebral ischemia/reperfusion injury in vivo and in vitro by inhibiting oxidative stress via the SIRT1/Nrf2 signaling pathway.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	124-128
34881386-13	2022	Besides, diosmetin increased the protein expressions of SIRT1, T-Nrf2, N-Nrf2, NQO1 and HO-1 both in vivo and in vitro.	diosmetin	9-18	sirtuin 1	Rattus norvegicus	56-61
34881386-13	2022	Besides, diosmetin increased the protein expressions of SIRT1, T-Nrf2, N-Nrf2, NQO1 and HO-1 both in vivo and in vitro.	diosmetin	9-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	65-69
34881386-13	2022	Besides, diosmetin increased the protein expressions of SIRT1, T-Nrf2, N-Nrf2, NQO1 and HO-1 both in vivo and in vitro.	diosmetin	9-18	NFE2 like bZIP transcription factor 2	Rattus norvegicus	73-77
34881386-13	2022	Besides, diosmetin increased the protein expressions of SIRT1, T-Nrf2, N-Nrf2, NQO1 and HO-1 both in vivo and in vitro.	diosmetin	9-18	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	79-83
34881386-13	2022	Besides, diosmetin increased the protein expressions of SIRT1, T-Nrf2, N-Nrf2, NQO1 and HO-1 both in vivo and in vitro.	diosmetin	9-18	heme oxygenase 1	Rattus norvegicus	88-92
34881386-14	2022	However, administration of EX527 or silencing the SIRT1 gene with its siRNA eliminated the beneficial effects of diosmetin.	diosmetin	113-122	sirtuin 1	Rattus norvegicus	50-55
34881386-16	2022	In conclusion, our data suggested that diosmetin could attenuate cerebral I/R injury by inhibiting oxidative stress via the SIRT1/Nrf2 signaling pathway.	diosmetin	39-48	sirtuin 1	Rattus norvegicus	124-129
34881386-16	2022	In conclusion, our data suggested that diosmetin could attenuate cerebral I/R injury by inhibiting oxidative stress via the SIRT1/Nrf2 signaling pathway.	diosmetin	39-48	NFE2 like bZIP transcription factor 2	Rattus norvegicus	130-134
33751333-2	2021	Once diosmetin has been identified as a novel TRPV1 antagonist, we evaluated the action of diosmetin from the inflammatory [ear oedema, myeloperoxidase (MPO) activity, histological changes, and cytokines levels] and oxidative [nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and SOD activities] parameters in mice exposed to UVB radiation (0.5 j/cm2).	diosmetin	5-14	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	46-51
33751333-4	2021	The topical treatment with the novel TRPV1 antagonist, diosmetin (1%; 15 mg/ear), reduced ear oedema, MPO activity, and MIP-2 and IL-1beta cytokines levels by 82 +- 8%, 59 +- 10%, 40 +- 12%, and 85 +- 9%, respectively.	diosmetin	55-64	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	37-42
33751333-4	2021	The topical treatment with the novel TRPV1 antagonist, diosmetin (1%; 15 mg/ear), reduced ear oedema, MPO activity, and MIP-2 and IL-1beta cytokines levels by 82 +- 8%, 59 +- 10%, 40 +- 12%, and 85 +- 9%, respectively.	diosmetin	55-64	myeloperoxidase	Mus musculus	102-105
33751333-4	2021	The topical treatment with the novel TRPV1 antagonist, diosmetin (1%; 15 mg/ear), reduced ear oedema, MPO activity, and MIP-2 and IL-1beta cytokines levels by 82 +- 8%, 59 +- 10%, 40 +- 12%, and 85 +- 9%, respectively.	diosmetin	55-64	chemokine (C-X-C motif) ligand 2	Mus musculus	120-125
33751333-4	2021	The topical treatment with the novel TRPV1 antagonist, diosmetin (1%; 15 mg/ear), reduced ear oedema, MPO activity, and MIP-2 and IL-1beta cytokines levels by 82 +- 8%, 59 +- 10%, 40 +- 12%, and 85 +- 9%, respectively.	diosmetin	55-64	interleukin 1 alpha	Mus musculus	130-138
33449987-0	2021	Diosmetin attenuates metabolic syndrome and left ventricular alterations via the suppression of angiotensin II/AT1 receptor/gp91phox/p-NF-kappaB protein expression in high-fat diet fed rats.	diosmetin	0-9	cytochrome b-245 beta chain	Rattus norvegicus	124-132
33449987-7	2021	Diosmetin also suppressed angiotensin-converting enzyme activity, plasma angiotensin II (Ang II) levels and angiotensin II type 1 (AT1) receptor protein expression in MS rats.	diosmetin	0-9	angiotensin I converting enzyme	Rattus norvegicus	26-55
33449987-7	2021	Diosmetin also suppressed angiotensin-converting enzyme activity, plasma angiotensin II (Ang II) levels and angiotensin II type 1 (AT1) receptor protein expression in MS rats.	diosmetin	0-9	angiotensinogen	Rattus norvegicus	73-87
33449987-7	2021	Diosmetin also suppressed angiotensin-converting enzyme activity, plasma angiotensin II (Ang II) levels and angiotensin II type 1 (AT1) receptor protein expression in MS rats.	diosmetin	0-9	angiotensinogen	Rattus norvegicus	89-95
33449987-7	2021	Diosmetin also suppressed angiotensin-converting enzyme activity, plasma angiotensin II (Ang II) levels and angiotensin II type 1 (AT1) receptor protein expression in MS rats.	diosmetin	0-9	angiotensin II receptor, type 1b	Rattus norvegicus	108-144
33449987-8	2021	Increases in superoxide (O2 -) formation, plasma malondialdehyde, plasma nitrate and nitrite and gp91phox expression induced by a HF diet were ameliorated in the diosmetin treated group.	diosmetin	162-171	cytochrome b-245 beta chain	Rattus norvegicus	97-105
33449987-9	2021	Inflammation indicated by an increased phospho nuclear factor kappa B (p-NF-kappaB) protein expression and cardiac TNF-alpha concentration was reduced in MS rats receiving diosmetin (p < 0.05).	diosmetin	172-181	tumor necrosis factor	Rattus norvegicus	115-124
33064975-6	2020	Further mechanistic studies showed that diosmetin inhibited the recruitment of RPA2 and RAD51, two critical factors involved in the HR repair pathway, upon the occurrence of DSBs.	diosmetin	40-49	replication protein A2	Homo sapiens	79-83
33404223-0	2021	Diosmetin Ameliorates Nonalcoholic Steatohepatitis through Modulating Lipogenesis and Inflammatory Response in a STAT1/CXCL10-Dependent Manner.	diosmetin	0-9	signal transducer and activator of transcription 1	Homo sapiens	113-118
33404223-0	2021	Diosmetin Ameliorates Nonalcoholic Steatohepatitis through Modulating Lipogenesis and Inflammatory Response in a STAT1/CXCL10-Dependent Manner.	diosmetin	0-9	C-X-C motif chemokine ligand 10	Homo sapiens	119-125
33045572-0	2020	Anti-inflammatory effects of natural flavonoid diosmetin in IL-4 and LPS-induced macrophage activation and atopic dermatitis model.	diosmetin	47-56	interleukin 4	Mus musculus	60-64
33045572-6	2020	Furthermore, immunohistochemical analysis using an anti-F4/80 antibody demonstrated that diosmetin significantly suppressed macrophage infiltration into the AD lesion.	diosmetin	89-98	adhesion G protein-coupled receptor E1	Mus musculus	56-61
33045572-7	2020	It was observed that the levels of pro-inflammatory cytokines (TNF-alpha, IL-4 and IL-1beta) in skin lesion decreased in response to treatment with diosmetin.	diosmetin	148-157	tumor necrosis factor	Mus musculus	63-72
33045572-7	2020	It was observed that the levels of pro-inflammatory cytokines (TNF-alpha, IL-4 and IL-1beta) in skin lesion decreased in response to treatment with diosmetin.	diosmetin	148-157	interleukin 4	Mus musculus	74-78
33045572-7	2020	It was observed that the levels of pro-inflammatory cytokines (TNF-alpha, IL-4 and IL-1beta) in skin lesion decreased in response to treatment with diosmetin.	diosmetin	148-157	interleukin 1 alpha	Mus musculus	83-91
33045572-8	2020	In addition, the anti-inflammatory effect of diosmetin was evaluated in LPS- or IL-4-induced a mouse macrophage cell line (raw 264.7).	diosmetin	45-54	interleukin 4	Mus musculus	80-84
33045572-9	2020	Diosmetin inhibited the production of nitric oxide and decreased the expression of inducible nitric oxide synthase (iNOS).	diosmetin	0-9	nitric oxide synthase 2, inducible	Mus musculus	83-114
33045572-9	2020	Diosmetin inhibited the production of nitric oxide and decreased the expression of inducible nitric oxide synthase (iNOS).	diosmetin	0-9	nitric oxide synthase 2, inducible	Mus musculus	116-120
33045572-10	2020	Diosmetin not only suppressed the phosphorylation of MAP kinase (ERK 1/2, p38 and JNK) but the activation of JAK/STAT signaling.	diosmetin	0-9	mitogen-activated protein kinase 3	Mus musculus	65-72
33045572-10	2020	Diosmetin not only suppressed the phosphorylation of MAP kinase (ERK 1/2, p38 and JNK) but the activation of JAK/STAT signaling.	diosmetin	0-9	mitogen-activated protein kinase 14	Mus musculus	74-77
33045572-10	2020	Diosmetin not only suppressed the phosphorylation of MAP kinase (ERK 1/2, p38 and JNK) but the activation of JAK/STAT signaling.	diosmetin	0-9	mitogen-activated protein kinase 8	Mus musculus	82-85
33045572-11	2020	The mRNA analysis demonstrated that diosmetin also reduced the level of inflammatory cytokines such as IL-1beta and IL-6.	diosmetin	36-45	interleukin 1 alpha	Mus musculus	103-111
33045572-11	2020	The mRNA analysis demonstrated that diosmetin also reduced the level of inflammatory cytokines such as IL-1beta and IL-6.	diosmetin	36-45	interleukin 6	Mus musculus	116-120
33064975-6	2020	Further mechanistic studies showed that diosmetin inhibited the recruitment of RPA2 and RAD51, two critical factors involved in the HR repair pathway, upon the occurrence of DSBs.	diosmetin	40-49	RAD51 recombinase	Homo sapiens	88-93
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	26-29
32938818-7	2020	Diosmetin or diosmin treatment also reduced IgE and IL-4 levels in AD-induced hairless mouse serum samples.	diosmetin	0-9	interleukin 4	Mus musculus	52-56
32938818-8	2020	However, in the in vitro assay, only diosmetin, not diosmin, reduced the expression level of IL-4 mRNA in RBL-2H3 cells.	diosmetin	37-46	interleukin 4	Rattus norvegicus	93-97
32679184-0	2020	Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.	diosmetin	36-45	S-phase kinase associated protein 2	Homo sapiens	10-14
32679184-0	2020	Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.	diosmetin	36-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	15-22
32679184-5	2020	We demonstrate that Diosmetin, a kind of phytoestrogens, notably downregulates the expression of SKP2, Bcr-Abl phosphorylation, and moderately downregulates the Bcr-Abl level.	diosmetin	20-29	S-phase kinase associated protein 2	Homo sapiens	97-101
32679184-5	2020	We demonstrate that Diosmetin, a kind of phytoestrogens, notably downregulates the expression of SKP2, Bcr-Abl phosphorylation, and moderately downregulates the Bcr-Abl level.	diosmetin	20-29	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	103-110
33182044-0	2020	Diosmetin alleviates acute kidney injury by promoting the TUG1/Nrf2/HO-1 pathway in sepsis rats.	diosmetin	0-9	taurine up-regulated 1	Rattus norvegicus	58-62
33182044-0	2020	Diosmetin alleviates acute kidney injury by promoting the TUG1/Nrf2/HO-1 pathway in sepsis rats.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	63-67
33182044-0	2020	Diosmetin alleviates acute kidney injury by promoting the TUG1/Nrf2/HO-1 pathway in sepsis rats.	diosmetin	0-9	heme oxygenase 1	Rattus norvegicus	68-72
33182044-10	2020	However, DIOS significantly reversed these effects caused by LPS treatment, and increased the expression of lncRNA-TUG1, but lncRNA-TUG1 silencing effectively reversed the effects of DIOS.	diosmetin	9-13	taurine up-regulated 1	Rattus norvegicus	115-119
33182044-14	2020	CONCLUSION: DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.	diosmetin	12-16	taurine up-regulated 1	Rattus norvegicus	69-73
33182044-14	2020	CONCLUSION: DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.	diosmetin	12-16	NFE2 like bZIP transcription factor 2	Rattus norvegicus	74-78
33182044-14	2020	CONCLUSION: DIOS may reduce sepsis-induced AKI through enhancing the TUG1/Nrf2/HO-1 pathway.	diosmetin	12-16	heme oxygenase 1	Rattus norvegicus	79-83
33209892-0	2020	Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats.	diosmetin	0-9	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	83-88
32679184-5	2020	We demonstrate that Diosmetin, a kind of phytoestrogens, notably downregulates the expression of SKP2, Bcr-Abl phosphorylation, and moderately downregulates the Bcr-Abl level.	diosmetin	20-29	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	161-168
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	monoamine oxidase B	Homo sapiens	49-53
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-63
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	monoamine oxidase B	Homo sapiens	176-180
32746771-6	2021	From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2.	diosmetin	76-85	AKT serine/threonine kinase 2	Homo sapiens	220-224
32746771-7	2021	This study mainly represents that Galuteolin and Linarin in the Akt pathway can be perceived for OSCC treatment and other five CYP inhibitors - Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin for the treatment of other diseases and cancers caused by overexpression of MAOB.	diosmetin	144-153	AKT serine/threonine kinase 1	Homo sapiens	64-67
32367620-3	2020	The secretion of inflammatory mediators increased in a coculture medium, however, diosmetin significantly reduced the levels of these inflammatory mediators such as nitric oxide (NO), tumor necrosis factor-alpha, and monocyte chemoattractant protein.	diosmetin	82-91	tumor necrosis factor	Homo sapiens	184-211
32627001-0	2020	Diosmetin alleviates hypoxia-induced myocardial apoptosis by inducing autophagy through AMPK activation.	diosmetin	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	88-92
32627001-9	2020	It was also found that the occurrence of autophagy was promoted when hypoxia-injured cells were treated with diosmetin alone, and results of the western blot analysis revealed that AMPK signaling was activated by diosmetin.	diosmetin	109-118	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	181-185
32627001-9	2020	It was also found that the occurrence of autophagy was promoted when hypoxia-injured cells were treated with diosmetin alone, and results of the western blot analysis revealed that AMPK signaling was activated by diosmetin.	diosmetin	213-222	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	181-185
32627001-10	2020	Administration of diosmetin together with an inhibitor of autophagy (3-methyladenine, 3-MA) or AMPK (Compound C) was able to decrease the diosmetin-induced autophagy as well as the cytoprotective effects in the hypoxia-injured cells.	diosmetin	138-147	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	95-99
32627001-12	2020	AMPK was demonstrated to regulate the observed effects caused by diosmetin.	diosmetin	65-74	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	0-4
32367620-4	2020	Diosmetin down-regulated the protein expression of inducible NO synthase in cocultured macrophages and adipocytes, and inhibited the phosphorylation of mitogen-activated protein kinases and the translocation of p65 and p50 to the nucleus.	diosmetin	0-9	nitric oxide synthase 2	Homo sapiens	51-72
32367620-4	2020	Diosmetin down-regulated the protein expression of inducible NO synthase in cocultured macrophages and adipocytes, and inhibited the phosphorylation of mitogen-activated protein kinases and the translocation of p65 and p50 to the nucleus.	diosmetin	0-9	RELA proto-oncogene, NF-kB subunit	Homo sapiens	211-214
32367620-4	2020	Diosmetin down-regulated the protein expression of inducible NO synthase in cocultured macrophages and adipocytes, and inhibited the phosphorylation of mitogen-activated protein kinases and the translocation of p65 and p50 to the nucleus.	diosmetin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	219-222
31906574-6	2020	Results: Diosmetin inhibited U251 cell proliferation, migration, and invasion in vitro, the TGF-beta signaling pathway, and Bcl-2 expression.	diosmetin	9-18	BCL2 apoptosis regulator	Homo sapiens	124-129
31833613-0	2020	Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-alpha-stimulated human rheumatoid arthritis fibroblast-like synoviocytes through regulating the Akt and NF-kappaB signaling pathways.	diosmetin	0-9	tumor necrosis factor	Homo sapiens	71-80
31833613-0	2020	Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-alpha-stimulated human rheumatoid arthritis fibroblast-like synoviocytes through regulating the Akt and NF-kappaB signaling pathways.	diosmetin	0-9	AKT serine/threonine kinase 1	Homo sapiens	171-174
31833613-0	2020	Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-alpha-stimulated human rheumatoid arthritis fibroblast-like synoviocytes through regulating the Akt and NF-kappaB signaling pathways.	diosmetin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	179-188
31833613-7	2020	Results showed that diosmetin inhibited tumor necrosis factor-alpha (TNF-alpha)-induced proliferation increase in MH7A cells in a dose-dependent manner.	diosmetin	20-29	tumor necrosis factor	Homo sapiens	40-67
31833613-7	2020	Results showed that diosmetin inhibited tumor necrosis factor-alpha (TNF-alpha)-induced proliferation increase in MH7A cells in a dose-dependent manner.	diosmetin	20-29	tumor necrosis factor	Homo sapiens	69-78
31833613-8	2020	Diosmetin treatment resulted in an increase in apoptotic rates and a reduction in TNF-alpha-induced production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells.	diosmetin	0-9	tumor necrosis factor	Homo sapiens	82-91
31833613-8	2020	Diosmetin treatment resulted in an increase in apoptotic rates and a reduction in TNF-alpha-induced production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells.	diosmetin	0-9	interleukin 1 beta	Homo sapiens	114-122
31833613-8	2020	Diosmetin treatment resulted in an increase in apoptotic rates and a reduction in TNF-alpha-induced production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells.	diosmetin	0-9	interleukin 6	Homo sapiens	124-128
31833613-8	2020	Diosmetin treatment resulted in an increase in apoptotic rates and a reduction in TNF-alpha-induced production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells.	diosmetin	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	130-134
31833613-8	2020	Diosmetin treatment resulted in an increase in apoptotic rates and a reduction in TNF-alpha-induced production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells.	diosmetin	0-9	matrix metallopeptidase 1	Homo sapiens	140-145
31833613-9	2020	Furthermore, diosmetin inhibited TNF-alpha-induced activation of protein kinase B (Akt) and nuclear factor-kappaB (NF-kappaB) pathways in MH7A cells.	diosmetin	13-22	tumor necrosis factor	Homo sapiens	33-42
31833613-9	2020	Furthermore, diosmetin inhibited TNF-alpha-induced activation of protein kinase B (Akt) and nuclear factor-kappaB (NF-kappaB) pathways in MH7A cells.	diosmetin	13-22	AKT serine/threonine kinase 1	Homo sapiens	83-86
31833613-9	2020	Furthermore, diosmetin inhibited TNF-alpha-induced activation of protein kinase B (Akt) and nuclear factor-kappaB (NF-kappaB) pathways in MH7A cells.	diosmetin	13-22	nuclear factor kappa B subunit 1	Homo sapiens	92-113
31833613-9	2020	Furthermore, diosmetin inhibited TNF-alpha-induced activation of protein kinase B (Akt) and nuclear factor-kappaB (NF-kappaB) pathways in MH7A cells.	diosmetin	13-22	nuclear factor kappa B subunit 1	Homo sapiens	115-124
31833613-10	2020	Suppression of Akt or NF-kappaB promoted apoptosis and inhibited TNF-alpha-induced proliferation increase and production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells, and diosmetin treatment enhanced these effects.	diosmetin	175-184	AKT serine/threonine kinase 1	Homo sapiens	15-18
31833613-10	2020	Suppression of Akt or NF-kappaB promoted apoptosis and inhibited TNF-alpha-induced proliferation increase and production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells, and diosmetin treatment enhanced these effects.	diosmetin	175-184	nuclear factor kappa B subunit 1	Homo sapiens	22-31
31833613-10	2020	Suppression of Akt or NF-kappaB promoted apoptosis and inhibited TNF-alpha-induced proliferation increase and production of IL-1beta, IL-6, IL-8, and MMP-1 in MH7A cells, and diosmetin treatment enhanced these effects.	diosmetin	175-184	tumor necrosis factor	Homo sapiens	65-74
31833613-11	2020	Taken together, these findings suggested that diosmetin exhibited anti-proliferative and anti-inflammatory effects via inhibiting the Akt and NF-kappaB pathways in MH7A cells.	diosmetin	46-55	AKT serine/threonine kinase 1	Homo sapiens	134-137
31833613-11	2020	Taken together, these findings suggested that diosmetin exhibited anti-proliferative and anti-inflammatory effects via inhibiting the Akt and NF-kappaB pathways in MH7A cells.	diosmetin	46-55	nuclear factor kappa B subunit 1	Homo sapiens	142-151
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	BCL2 apoptosis regulator	Homo sapiens	88-93
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	cyclin dependent kinase 1	Homo sapiens	95-99
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	cyclin B1	Homo sapiens	101-109
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	BCL2 associated X, apoptosis regulator	Homo sapiens	149-152
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	caspase 8	Homo sapiens	180-188
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	collagen type XI alpha 2 chain	Homo sapiens	198-202
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	BCL2 antagonist/killer 1	Homo sapiens	204-207
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	tumor protein p53	Homo sapiens	209-212
32547191-11	2020	Western blot results showed that DIOS significantly suppressed the expression levels of Bcl-2, cdc2, cyclinB1, and promoted the expression levels of Bax, cleaved-caspase3, cleaved-caspase8, cleaved-PARP, Bak, P53, and P21.	diosmetin	33-37	H3 histone pseudogene 16	Homo sapiens	218-221
32547191-14	2020	Furthermore, DIOS could induce G2/M cell cycle arrest in HepG2 cell via targeting Chk2.	diosmetin	13-17	checkpoint kinase 2	Homo sapiens	82-86
31906574-9	2020	Conclusion: The results of this study suggest that diosmetin suppresses the growth of glioma cells in vitro and in vivo, possibly by activating E-cadherin expression and inhibiting the TGF-beta signaling pathway.	diosmetin	51-60	cadherin 1	Homo sapiens	144-154
31228803-10	2019	Notably, diosmetin induced the normalization of tumor vasculature through the downregulation of angiopoietin-2 and the improvement of pericyte coverage, leading to suppression of metastasis formation in lungs and lymph nodes.	diosmetin	9-18	angiopoietin 2	Mus musculus	96-110
32223728-0	2020	Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells.	diosmetin	0-9	AKT serine/threonine kinase 1	Homo sapiens	46-49
32223728-0	2020	Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells.	diosmetin	0-9	tumor protein p53	Homo sapiens	70-73
32223728-8	2020	In addition, it was observed that the anticancer effect of DIOS was significantly enhanced by the p53 activator, but inhibited by the p53 inhibitor.	diosmetin	59-63	tumor protein p53	Homo sapiens	98-101
32223728-8	2020	In addition, it was observed that the anticancer effect of DIOS was significantly enhanced by the p53 activator, but inhibited by the p53 inhibitor.	diosmetin	59-63	tumor protein p53	Homo sapiens	134-137
32223728-9	2020	CONCLUSION: Our data suggested that DIOS induced apoptosis in renal carcinoma ACHN cells by reducing AKT phosphorylation through p53 upregulation.	diosmetin	36-40	AKT serine/threonine kinase 1	Homo sapiens	101-104
32223728-9	2020	CONCLUSION: Our data suggested that DIOS induced apoptosis in renal carcinoma ACHN cells by reducing AKT phosphorylation through p53 upregulation.	diosmetin	36-40	tumor protein p53	Homo sapiens	129-132
31306971-7	2019	Accordingly, subsequent experiments with diosmetin revealed that it was a selective estrogen receptor-beta agonist that stimulated osteoblast differentiation and suppressed sclerostin the anti-osteoblastogenic Wnt antagonist.	diosmetin	41-50	estrogen receptor 2	Rattus norvegicus	84-106
31306971-7	2019	Accordingly, subsequent experiments with diosmetin revealed that it was a selective estrogen receptor-beta agonist that stimulated osteoblast differentiation and suppressed sclerostin the anti-osteoblastogenic Wnt antagonist.	diosmetin	41-50	Wnt family member 2	Rattus norvegicus	210-213
30515812-6	2019	In this study project, we found that DIO could inhibit osteoclastic formation induced by receptor activator of nuclear factor kappa-B ligand (RANKL) in a dose-dependent manner.	diosmetin	37-40	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	89-140
31177049-0	2019	Profiling and comparison of the metabolites of diosmetin and diosmin in rat urine, plasma and feces using UHPLC-LTQ-Orbitrap MSn.	diosmetin	47-56	moesin	Rattus norvegicus	125-128
31177049-3	2019	In this study, metabolites of diosmin and diosmetin were identified using an UHPLC-LTQ-Orbitrap MSn strategy coupled with multiple metabolite templates, extracted ion chromatograms (EICs) and diagnostic product ions (DPIs).	diosmetin	42-51	moesin	Rattus norvegicus	96-99
30515812-6	2019	In this study project, we found that DIO could inhibit osteoclastic formation induced by receptor activator of nuclear factor kappa-B ligand (RANKL) in a dose-dependent manner.	diosmetin	37-40	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	142-147
30515812-7	2019	The expression of the osteoclast differentiation marker genes, cathepsin K, nuclear factor of activated T-cells 1 (NFATc1), Acp5, Ctr, Atp6v0d2, and Mmp9 were also decreased by the treatment of DIO.	diosmetin	194-197	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	135-143
30515812-7	2019	The expression of the osteoclast differentiation marker genes, cathepsin K, nuclear factor of activated T-cells 1 (NFATc1), Acp5, Ctr, Atp6v0d2, and Mmp9 were also decreased by the treatment of DIO.	diosmetin	194-197	matrix metallopeptidase 9	Mus musculus	149-153
30515812-9	2019	Further, the western blotting showed that DIO inhibits the phosphorylation of the mitogen-activated protein kinases signaling pathway induced by RANKL, accompanied by the downregulation of NFATc1 and c-Fos expression.	diosmetin	42-45	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	145-150
30515812-9	2019	Further, the western blotting showed that DIO inhibits the phosphorylation of the mitogen-activated protein kinases signaling pathway induced by RANKL, accompanied by the downregulation of NFATc1 and c-Fos expression.	diosmetin	42-45	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	189-195
30515812-9	2019	Further, the western blotting showed that DIO inhibits the phosphorylation of the mitogen-activated protein kinases signaling pathway induced by RANKL, accompanied by the downregulation of NFATc1 and c-Fos expression.	diosmetin	42-45	FBJ osteosarcoma oncogene	Mus musculus	200-205
30515812-10	2019	We also found that DIO could reduce the accumulation of reactive oxygen species (ROS) induced by RANKL.	diosmetin	19-22	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	97-102
31295840-7	2019	Anti-apoptotic Bcl-2 protein was significantly downregulated, while apoptotic protein (Bax) was significantly overexpressed in nude mice treated with 100 mg/kg Dis as compared to untreated mice.	diosmetin	160-163	B cell leukemia/lymphoma 2	Mus musculus	15-20
31295840-7	2019	Anti-apoptotic Bcl-2 protein was significantly downregulated, while apoptotic protein (Bax) was significantly overexpressed in nude mice treated with 100 mg/kg Dis as compared to untreated mice.	diosmetin	160-163	BCL2-associated X protein	Mus musculus	87-90
30914630-0	2019	Diosmetin Suppresses Neuronal Apoptosis and Inflammation by Modulating the Phosphoinositide 3-Kinase (PI3K)/AKT/Nuclear Factor-kappaB (NF-kappaB) Signaling Pathway in a Rat Model of Pneumococcal Meningitis.	diosmetin	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	75-100
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	BCL2 apoptosis regulator	Homo sapiens	83-88
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	cyclin D1	Homo sapiens	93-102
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	tumor protein p53	Homo sapiens	128-131
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	BCL2 associated X, apoptosis regulator	Homo sapiens	133-136
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	caspase 3	Homo sapiens	138-147
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	caspase 9	Homo sapiens	157-166
31228347-9	2019	Moreover, diosmetin treatment significantly downregulated the expression levels of Bcl-2 and Cyclin D1, and upregulated that of p53, Bax, caspase 3, cleaved caspase 9, and cleaved caspase 3.	diosmetin	10-19	caspase 3	Homo sapiens	180-189
30825187-0	2019	Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.	diosmetin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	125-129
30825187-10	2019	Diosmetin induced ROS production in NSCLC cells probably via reducing Nrf2 stability through disruption of the PI3K/Akt/GSK-3beta pathway.	diosmetin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	70-74
30825187-10	2019	Diosmetin induced ROS production in NSCLC cells probably via reducing Nrf2 stability through disruption of the PI3K/Akt/GSK-3beta pathway.	diosmetin	0-9	thymoma viral proto-oncogene 1	Mus musculus	116-119
30825187-10	2019	Diosmetin induced ROS production in NSCLC cells probably via reducing Nrf2 stability through disruption of the PI3K/Akt/GSK-3beta pathway.	diosmetin	0-9	glycogen synthase kinase 3 alpha	Mus musculus	120-129
30825187-13	2019	CONCLUSIONS AND IMPLICATIONS: Diosmetin selectively induced apoptosis and enhanced the efficacy of paclitaxel in NSCLC cells via ROS accumulation through disruption of the PI3K/Akt/GSK-3beta/Nrf2 pathway.	diosmetin	30-39	thymoma viral proto-oncogene 1	Mus musculus	177-180
30825187-13	2019	CONCLUSIONS AND IMPLICATIONS: Diosmetin selectively induced apoptosis and enhanced the efficacy of paclitaxel in NSCLC cells via ROS accumulation through disruption of the PI3K/Akt/GSK-3beta/Nrf2 pathway.	diosmetin	30-39	glycogen synthase kinase 3 alpha	Mus musculus	181-190
30825187-13	2019	CONCLUSIONS AND IMPLICATIONS: Diosmetin selectively induced apoptosis and enhanced the efficacy of paclitaxel in NSCLC cells via ROS accumulation through disruption of the PI3K/Akt/GSK-3beta/Nrf2 pathway.	diosmetin	30-39	nuclear factor, erythroid derived 2, like 2	Mus musculus	191-195
30914630-0	2019	Diosmetin Suppresses Neuronal Apoptosis and Inflammation by Modulating the Phosphoinositide 3-Kinase (PI3K)/AKT/Nuclear Factor-kappaB (NF-kappaB) Signaling Pathway in a Rat Model of Pneumococcal Meningitis.	diosmetin	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	108-111
30914630-8	2019	In the rat hippocampal tissue, levels of Akt, PI3K, MyD88 and NF-kappaB, and the number of TUNEL-positive apoptotic cells were significantly reduced in the diosmetin-treated group compared with negative control group (p&lt;0.01).	diosmetin	156-165	AKT serine/threonine kinase 1	Rattus norvegicus	41-44
30914630-8	2019	In the rat hippocampal tissue, levels of Akt, PI3K, MyD88 and NF-kappaB, and the number of TUNEL-positive apoptotic cells were significantly reduced in the diosmetin-treated group compared with negative control group (p&lt;0.01).	diosmetin	156-165	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	52-57
30914630-9	2019	In a rat model of bacterial meningitis due to S. pneumoniae, diosmetin reduced neuroinflammation, and neuronal apoptosis by modulating the PI3K/AKT/NF-kappaB signaling pathway.	diosmetin	61-70	AKT serine/threonine kinase 1	Rattus norvegicus	144-147
30362618-8	2019	Cotreatments of diosmetin and betaine showed the most robust additive effects, as confirmed by three independent functional assays in primary PEX1-G843D patient cells, but neither agent was active alone or in combination in patient cells homozygous for the PEX1 c.2097_2098insT null allele.	diosmetin	16-25	peroxisomal biogenesis factor 1	Homo sapiens	142-146
30362618-8	2019	Cotreatments of diosmetin and betaine showed the most robust additive effects, as confirmed by three independent functional assays in primary PEX1-G843D patient cells, but neither agent was active alone or in combination in patient cells homozygous for the PEX1 c.2097_2098insT null allele.	diosmetin	16-25	peroxisomal biogenesis factor 1	Homo sapiens	257-261
30362618-9	2019	Moreover, diosmetin treatment increased PEX1, PEX6, and PEX5 protein levels in PEX1-G843D patient cells, but none of these proteins increased in PEX1 null cells.	diosmetin	10-19	peroxisomal biogenesis factor 1	Homo sapiens	40-44
30362618-9	2019	Moreover, diosmetin treatment increased PEX1, PEX6, and PEX5 protein levels in PEX1-G843D patient cells, but none of these proteins increased in PEX1 null cells.	diosmetin	10-19	peroxisomal biogenesis factor 6	Homo sapiens	46-50
30362618-9	2019	Moreover, diosmetin treatment increased PEX1, PEX6, and PEX5 protein levels in PEX1-G843D patient cells, but none of these proteins increased in PEX1 null cells.	diosmetin	10-19	peroxisomal biogenesis factor 5	Homo sapiens	56-60
30362618-9	2019	Moreover, diosmetin treatment increased PEX1, PEX6, and PEX5 protein levels in PEX1-G843D patient cells, but none of these proteins increased in PEX1 null cells.	diosmetin	10-19	peroxisomal biogenesis factor 1	Homo sapiens	79-83
30362618-9	2019	Moreover, diosmetin treatment increased PEX1, PEX6, and PEX5 protein levels in PEX1-G843D patient cells, but none of these proteins increased in PEX1 null cells.	diosmetin	10-19	peroxisomal biogenesis factor 1	Homo sapiens	79-83
30362618-10	2019	We propose that diosmetin acts as a pharmacological chaperone that improves the stability, conformation, and functions of PEX1/PEX6 exportomer complexes required for peroxisome assembly.	diosmetin	16-25	peroxisomal biogenesis factor 1	Homo sapiens	122-126
30362618-10	2019	We propose that diosmetin acts as a pharmacological chaperone that improves the stability, conformation, and functions of PEX1/PEX6 exportomer complexes required for peroxisome assembly.	diosmetin	16-25	peroxisomal biogenesis factor 6	Homo sapiens	127-131
30362618-11	2019	We suggest that diosmetin, in clinical use for chronic venous disease, and related flavonoids warrant further preclinical investigation for the treatment of PEX1-G843D-associated ZSD.	diosmetin	16-25	peroxisomal biogenesis factor 1	Homo sapiens	157-161
30624931-5	2019	The seven most potent IP6K inhibitors were incubated with intact HCT116 cells at concentrations of 2.5 muM; diosmetin was the most selective and effective IP6K inhibitor (&gt;70% reduction in activity).	diosmetin	108-117	diphosphoinositol pentakisphosphate kinase 1	Homo sapiens	22-26
29767250-2	2018	In this study, using western blot analysis for protein expression and flow cytometry for cell cycle analysis, we determined that the treatment of the LNCaP and PC-3 prostate cancer cells with diosmetin resulted in a marked decrease in cyclin D1, Cdk2 and Cdk4 expression levels (these proteins remain active in the G0-G1 phases of the cell cycle).	diosmetin	192-201	cyclin D1	Homo sapiens	235-244
30624931-5	2019	The seven most potent IP6K inhibitors were incubated with intact HCT116 cells at concentrations of 2.5 muM; diosmetin was the most selective and effective IP6K inhibitor (&gt;70% reduction in activity).	diosmetin	108-117	diphosphoinositol pentakisphosphate kinase 1	Homo sapiens	155-159
30278036-0	2018	Diosmetin Attenuates Akt Signaling Pathway by Modulating Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kappaB)/Inducible Nitric Oxide Synthase (iNOS) in Streptozotocin (STZ)-Induced Diabetic Nephropathy Mice.	diosmetin	0-9	thymoma viral proto-oncogene 1	Mus musculus	21-24
30278036-0	2018	Diosmetin Attenuates Akt Signaling Pathway by Modulating Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kappaB)/Inducible Nitric Oxide Synthase (iNOS) in Streptozotocin (STZ)-Induced Diabetic Nephropathy Mice.	diosmetin	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	121-130
30278036-0	2018	Diosmetin Attenuates Akt Signaling Pathway by Modulating Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kappaB)/Inducible Nitric Oxide Synthase (iNOS) in Streptozotocin (STZ)-Induced Diabetic Nephropathy Mice.	diosmetin	0-9	nitric oxide synthase 2, inducible	Mus musculus	132-163
30278036-0	2018	Diosmetin Attenuates Akt Signaling Pathway by Modulating Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kappaB)/Inducible Nitric Oxide Synthase (iNOS) in Streptozotocin (STZ)-Induced Diabetic Nephropathy Mice.	diosmetin	0-9	nitric oxide synthase 2, inducible	Mus musculus	165-169
30278036-9	2018	Expression of Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) was significantly reduced and inducible nitric oxide synthase (iNOS) was enhanced in the tissue homogenate of diosmetin-treated mice compared to the negative control group.	diosmetin	207-216	thymoma viral proto-oncogene 1	Mus musculus	14-17
30278036-9	2018	Expression of Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) was significantly reduced and inducible nitric oxide synthase (iNOS) was enhanced in the tissue homogenate of diosmetin-treated mice compared to the negative control group.	diosmetin	207-216	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	86-95
30278036-9	2018	Expression of Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) was significantly reduced and inducible nitric oxide synthase (iNOS) was enhanced in the tissue homogenate of diosmetin-treated mice compared to the negative control group.	diosmetin	207-216	nitric oxide synthase 2, inducible	Mus musculus	127-158
30278036-9	2018	Expression of Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) was significantly reduced and inducible nitric oxide synthase (iNOS) was enhanced in the tissue homogenate of diosmetin-treated mice compared to the negative control group.	diosmetin	207-216	nitric oxide synthase 2, inducible	Mus musculus	160-164
30278036-10	2018	Data from immunohistochemical analysis suggest that the expressions of NF-kappaB was significantly reduced in tissues of the diosmetin-treated group compared to the negative control group.	diosmetin	125-134	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-80
30278036-11	2018	CONCLUSIONS Our study shows that diosmetin protects against renal injury in STZ-induced diabetic nephropathy mice by modulating the Akt/NF-kappaB/iNOS signaling pathway.	diosmetin	33-42	thymoma viral proto-oncogene 1	Mus musculus	132-135
30278036-11	2018	CONCLUSIONS Our study shows that diosmetin protects against renal injury in STZ-induced diabetic nephropathy mice by modulating the Akt/NF-kappaB/iNOS signaling pathway.	diosmetin	33-42	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	136-145
30278036-11	2018	CONCLUSIONS Our study shows that diosmetin protects against renal injury in STZ-induced diabetic nephropathy mice by modulating the Akt/NF-kappaB/iNOS signaling pathway.	diosmetin	33-42	nitric oxide synthase 2, inducible	Mus musculus	146-150
30447303-13	2019	In conclusion, our results support the antinociceptive properties of diosmetin which seems to occur via TRPV1 antagonist in mice.	diosmetin	69-78	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	104-109
29738867-4	2018	We have identified eight bioactive compounds (Apigenin, Dihydromyricetin, Diosmetin, Hesperidin, Hesperitin, Naringenin, Phlorizi, and Quercetin) as the potential inhibitors of PLK-1.	diosmetin	74-83	polo like kinase 1	Homo sapiens	177-182
29767250-4	2018	The treatment of prostate cancer cells with diosmetin set in motion an apoptotic machinery by inhibiting X-linked inhibitor of apoptosis (XIAP) and increasing cleaved PARP and cleaved caspase-3 expression levels.	diosmetin	44-53	X-linked inhibitor of apoptosis	Homo sapiens	105-136
29767250-4	2018	The treatment of prostate cancer cells with diosmetin set in motion an apoptotic machinery by inhibiting X-linked inhibitor of apoptosis (XIAP) and increasing cleaved PARP and cleaved caspase-3 expression levels.	diosmetin	44-53	X-linked inhibitor of apoptosis	Homo sapiens	138-142
29767250-4	2018	The treatment of prostate cancer cells with diosmetin set in motion an apoptotic machinery by inhibiting X-linked inhibitor of apoptosis (XIAP) and increasing cleaved PARP and cleaved caspase-3 expression levels.	diosmetin	44-53	collagen type XI alpha 2 chain	Homo sapiens	167-171
29767250-2	2018	In this study, using western blot analysis for protein expression and flow cytometry for cell cycle analysis, we determined that the treatment of the LNCaP and PC-3 prostate cancer cells with diosmetin resulted in a marked decrease in cyclin D1, Cdk2 and Cdk4 expression levels (these proteins remain active in the G0-G1 phases of the cell cycle).	diosmetin	192-201	cyclin dependent kinase 2	Homo sapiens	246-250
29767250-2	2018	In this study, using western blot analysis for protein expression and flow cytometry for cell cycle analysis, we determined that the treatment of the LNCaP and PC-3 prostate cancer cells with diosmetin resulted in a marked decrease in cyclin D1, Cdk2 and Cdk4 expression levels (these proteins remain active in the G0-G1 phases of the cell cycle).	diosmetin	192-201	cyclin dependent kinase 4	Homo sapiens	255-259
29767250-3	2018	These changes were accompanied by a decrease in c-Myc and Bcl-2 expression, and by an increase in Bax, p27Kip1 and FOXO3a protein expression, which suggests the potential modulatory effects of diosmetin on protein transcription.	diosmetin	193-202	BCL2 associated X, apoptosis regulator	Homo sapiens	98-101
29767250-3	2018	These changes were accompanied by a decrease in c-Myc and Bcl-2 expression, and by an increase in Bax, p27Kip1 and FOXO3a protein expression, which suggests the potential modulatory effects of diosmetin on protein transcription.	diosmetin	193-202	cyclin dependent kinase inhibitor 1B	Homo sapiens	103-110
29767250-3	2018	These changes were accompanied by a decrease in c-Myc and Bcl-2 expression, and by an increase in Bax, p27Kip1 and FOXO3a protein expression, which suggests the potential modulatory effects of diosmetin on protein transcription.	diosmetin	193-202	forkhead box O3	Homo sapiens	115-121
29710853-15	2018	Hence, the hepatoprotective mechanism of CJF against CCl4-induced acute liver damage might be involved in restoring the activities and protein expression of the hepatic antioxidant defense system and inhibiting hepatic inflammation, and these hepatoprotective effects are related to the contents of silibinin diastereomers and diosmetin.	diosmetin	327-336	chemokine (C-C motif) ligand 4	Mus musculus	53-57
29710546-0	2018	Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin.	diosmetin	31-40	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93
29710546-5	2018	In this study, the inhibitory action of DIO and SIL on CYP2C9-catalyzed metabolism of diclofenac to 4"-hydroxydiclofenac was examined, using warfarin as a positive control.	diosmetin	40-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	55-61
29710546-7	2018	It is demonstrated that DIO and SIL are potent inhibitors of CYP2C9 enzyme and are able to displace the Site I ligand warfarin from human serum albumin.	diosmetin	24-27	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-67
28365974-0	2018	Diosmetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury through Activating the Nrf2 Pathway and Inhibiting the NLRP3 Inflammasome.	diosmetin	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	89-93
29568961-0	2018	Cytoprotective effects of diosmetin against hydrogen peroxide-induced L02 cell oxidative damage via activation of the Nrf2-ARE signaling pathway.	diosmetin	26-35	NFE2 like bZIP transcription factor 2	Homo sapiens	118-122
29568961-10	2018	Furthermore, pretreatment with diosmetin elevated mRNA and protein expression levels of Nrf2, HO-1 and NQO1.	diosmetin	31-40	NFE2 like bZIP transcription factor 2	Homo sapiens	88-92
29568961-10	2018	Furthermore, pretreatment with diosmetin elevated mRNA and protein expression levels of Nrf2, HO-1 and NQO1.	diosmetin	31-40	heme oxygenase 1	Homo sapiens	94-98
29568961-10	2018	Furthermore, pretreatment with diosmetin elevated mRNA and protein expression levels of Nrf2, HO-1 and NQO1.	diosmetin	31-40	NAD(P)H quinone dehydrogenase 1	Homo sapiens	103-107
29568961-11	2018	The present study is the first, to the best of our knowledge, to demonstrate that activation of the Nrf2/NQO1-HO-1 signaling pathway maybe involved in the cytoprotective effects of diosmetin against oxidative stress.	diosmetin	181-190	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
29568961-11	2018	The present study is the first, to the best of our knowledge, to demonstrate that activation of the Nrf2/NQO1-HO-1 signaling pathway maybe involved in the cytoprotective effects of diosmetin against oxidative stress.	diosmetin	181-190	NAD(P)H quinone dehydrogenase 1	Homo sapiens	105-109
29568961-11	2018	The present study is the first, to the best of our knowledge, to demonstrate that activation of the Nrf2/NQO1-HO-1 signaling pathway maybe involved in the cytoprotective effects of diosmetin against oxidative stress.	diosmetin	181-190	heme oxygenase 1	Homo sapiens	110-114
29412683-3	2018	Diosmetin, a citrus flavone, induced apoptosis characterized by increases in caspases 8 and 3/7 and the death inducing cytokine TNFalpha.	diosmetin	0-9	caspase 8	Mus musculus	77-93
29412683-3	2018	Diosmetin, a citrus flavone, induced apoptosis characterized by increases in caspases 8 and 3/7 and the death inducing cytokine TNFalpha.	diosmetin	0-9	tumor necrosis factor	Mus musculus	128-136
29412683-6	2018	In summary, these studies highlight diosmetin as a novel therapeutic that induces apoptosis through estrogen receptor beta.	diosmetin	36-45	estrogen receptor 2 (beta)	Mus musculus	100-122
28365974-0	2018	Diosmetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury through Activating the Nrf2 Pathway and Inhibiting the NLRP3 Inflammasome.	diosmetin	0-9	NLR family, pyrin domain containing 3	Mus musculus	121-126
28365974-7	2018	Additionally, increased MPO, MDA and ROS levels induced by LPS were also markly suppressed by diosmetin.	diosmetin	94-103	myeloperoxidase	Mus musculus	24-27
28365974-8	2018	Furthermore, diosmetin significantly increased the expression of Nrf2 along with its target gene HO-1 and blocked the activation of NLRP3 inflammasome in the lung tissues, which might be central to the protective effects of diosmetin.	diosmetin	13-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	65-69
28365974-8	2018	Furthermore, diosmetin significantly increased the expression of Nrf2 along with its target gene HO-1 and blocked the activation of NLRP3 inflammasome in the lung tissues, which might be central to the protective effects of diosmetin.	diosmetin	13-22	heme oxygenase 1	Mus musculus	97-101
28365974-8	2018	Furthermore, diosmetin significantly increased the expression of Nrf2 along with its target gene HO-1 and blocked the activation of NLRP3 inflammasome in the lung tissues, which might be central to the protective effects of diosmetin.	diosmetin	13-22	NLR family, pyrin domain containing 3	Mus musculus	132-137
28365974-8	2018	Furthermore, diosmetin significantly increased the expression of Nrf2 along with its target gene HO-1 and blocked the activation of NLRP3 inflammasome in the lung tissues, which might be central to the protective effects of diosmetin.	diosmetin	224-233	nuclear factor, erythroid derived 2, like 2	Mus musculus	65-69
28365974-8	2018	Furthermore, diosmetin significantly increased the expression of Nrf2 along with its target gene HO-1 and blocked the activation of NLRP3 inflammasome in the lung tissues, which might be central to the protective effects of diosmetin.	diosmetin	224-233	heme oxygenase 1	Mus musculus	97-101
28365974-8	2018	Furthermore, diosmetin significantly increased the expression of Nrf2 along with its target gene HO-1 and blocked the activation of NLRP3 inflammasome in the lung tissues, which might be central to the protective effects of diosmetin.	diosmetin	224-233	NLR family, pyrin domain containing 3	Mus musculus	132-137
28365974-9	2018	Further supporting these results, in vitro experiments also showed that diosmetin activated Nrf2 and HO-1, as well as inhibited the NLRP3 inflammasome in both RAW264.7 and A549 cells.	diosmetin	72-81	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
28365974-9	2018	Further supporting these results, in vitro experiments also showed that diosmetin activated Nrf2 and HO-1, as well as inhibited the NLRP3 inflammasome in both RAW264.7 and A549 cells.	diosmetin	72-81	heme oxygenase 1	Mus musculus	101-105
28365974-9	2018	Further supporting these results, in vitro experiments also showed that diosmetin activated Nrf2 and HO-1, as well as inhibited the NLRP3 inflammasome in both RAW264.7 and A549 cells.	diosmetin	72-81	NLR family, pyrin domain containing 3	Mus musculus	132-137
28365974-10	2018	The present study highlights the protective effects of diosmetin on LPS-induced ALI via activation of Nrf2 and inhibition of NLRP3 inflammasome, bringing up the hope of its application as a therapeutic drug towards LPS-induced ALI.	diosmetin	55-64	nuclear factor, erythroid derived 2, like 2	Mus musculus	102-106
28365974-10	2018	The present study highlights the protective effects of diosmetin on LPS-induced ALI via activation of Nrf2 and inhibition of NLRP3 inflammasome, bringing up the hope of its application as a therapeutic drug towards LPS-induced ALI.	diosmetin	55-64	NLR family, pyrin domain containing 3	Mus musculus	125-130
29173156-8	2018	The RMSD and MM-GBSA results from molecular dymamic simulations indicated that the docking pose of diosmetin-AChE complex displayed highly stable, which can be used for validating the accuracy of molecular docking study.	diosmetin	99-108	acetylcholinesterase (Cartwright blood group)	Homo sapiens	109-113
29173156-10	2018	CONCLUSION: The obtained results revealed that all the four compounds exhibited modest AChE inhibitory activity, among which Diosmetin manifested remarkable anti-AChE activity, comparable with the reference compound, Physostigmine.	diosmetin	125-134	acetylcholinesterase (Cartwright blood group)	Homo sapiens	87-91
29173156-10	2018	CONCLUSION: The obtained results revealed that all the four compounds exhibited modest AChE inhibitory activity, among which Diosmetin manifested remarkable anti-AChE activity, comparable with the reference compound, Physostigmine.	diosmetin	125-134	acetylcholinesterase (Cartwright blood group)	Homo sapiens	162-166
28835383-4	2017	Mechanistically, we demonstrated that diosmetin targets estrogen receptor (ER) beta.	diosmetin	38-47	estrogen receptor 2	Homo sapiens	56-83
28835383-5	2017	ERbeta expression conferred cell sensitivity, as patient-derived AML cells with high levels of ERbeta were sensitive, whereas cells with low ERbeta were insensitive to diosmetin.	diosmetin	168-177	estrogen receptor 2	Homo sapiens	0-6
28430612-4	2017	In addition, diosmetin prevented the expression of phosphorylated IKK, IkappaBalpha, and NF-kappaB p65 in the NF-kappaB signaling pathway, and JNK and p38 in the MAPK signaling pathway.	diosmetin	13-22	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	71-83
28624062-13	2017	CONCLUSIONS: The renoprotective effects of diosmetin involved suppression of the nuclear factor-kappaB and mitochondrial apoptosis pathways, as well as activation of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway.	diosmetin	43-52	heme oxygenase 1	Mus musculus	214-230
28245756-0	2017	Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	47-53
28245756-0	2017	Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	54-60
28245756-0	2017	Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells.	diosmetin	0-9	tumor protein p53	Homo sapiens	68-71
28245756-6	2017	The data reveal the new evidence that cytochrome P450 CYP1A regulation by P53 enzyme plays an important role in Diosmetin anti-cancer activity of HepG2 cells.	diosmetin	112-121	tumor protein p53	Homo sapiens	74-77
28867436-4	2017	Diosmetin showed strong inhibition of CYP1A2 in a concentration-dependent manner.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-44
28867436-8	2017	In addition, the inhibitory effects of diosmetin on OATP and OCT1 were weak, and it had little effect on NTCP.	diosmetin	39-48	solute carrier family 22 member 1	Homo sapiens	61-65
28867436-9	2017	This finding indicated that drug-drug interactions induced by diosmetin may occur through co-administration of drugs metabolized by CYP1A2.	diosmetin	62-71	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	132-138
28430612-4	2017	In addition, diosmetin prevented the expression of phosphorylated IKK, IkappaBalpha, and NF-kappaB p65 in the NF-kappaB signaling pathway, and JNK and p38 in the MAPK signaling pathway.	diosmetin	13-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
28430612-4	2017	In addition, diosmetin prevented the expression of phosphorylated IKK, IkappaBalpha, and NF-kappaB p65 in the NF-kappaB signaling pathway, and JNK and p38 in the MAPK signaling pathway.	diosmetin	13-22	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	99-102
28430612-4	2017	In addition, diosmetin prevented the expression of phosphorylated IKK, IkappaBalpha, and NF-kappaB p65 in the NF-kappaB signaling pathway, and JNK and p38 in the MAPK signaling pathway.	diosmetin	13-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	110-119
28430612-4	2017	In addition, diosmetin prevented the expression of phosphorylated IKK, IkappaBalpha, and NF-kappaB p65 in the NF-kappaB signaling pathway, and JNK and p38 in the MAPK signaling pathway.	diosmetin	13-22	mitogen-activated protein kinase 14	Mus musculus	151-154
28101201-0	2016	Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells.	diosmetin	0-9	mechanistic target of rapamycin kinase	Homo sapiens	92-121
28240165-0	2017	Diosmetin, a Potential p53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells.	diosmetin	0-9	tumor protein p53	Homo sapiens	23-26
28240165-4	2017	Meanwhile, Dios-induced liver cancer cell apoptosis was related with the p53 activation.	diosmetin	11-15	tumor protein p53	Homo sapiens	73-76
28101201-4	2016	The effects of DIOS treatment on HepG2 cell proliferation and apoptosis rates were analyzed using MTT assays and Annexin V staining, respectively.	diosmetin	15-19	annexin A5	Homo sapiens	113-122
28101201-11	2016	In conclusion, DIOS inhibits cell proliferation and induces apoptosis in HepG2 cells via regulation of the mTOR pathway.	diosmetin	15-19	mechanistic target of rapamycin kinase	Homo sapiens	107-111
28101238-0	2016	Diosmetin triggers cell apoptosis by activation of the p53/Bcl-2 pathway and inactivation of the Notch3/NF-kappaB pathway in HepG2 cells.	diosmetin	0-9	tumor protein p53	Homo sapiens	55-58
28101238-0	2016	Diosmetin triggers cell apoptosis by activation of the p53/Bcl-2 pathway and inactivation of the Notch3/NF-kappaB pathway in HepG2 cells.	diosmetin	0-9	BCL2 apoptosis regulator	Homo sapiens	59-64
28101238-0	2016	Diosmetin triggers cell apoptosis by activation of the p53/Bcl-2 pathway and inactivation of the Notch3/NF-kappaB pathway in HepG2 cells.	diosmetin	0-9	notch receptor 3	Homo sapiens	97-103
28101238-0	2016	Diosmetin triggers cell apoptosis by activation of the p53/Bcl-2 pathway and inactivation of the Notch3/NF-kappaB pathway in HepG2 cells.	diosmetin	0-9	nuclear factor kappa B subunit 1	Homo sapiens	104-113
28101238-5	2016	Western blotting was performed to evaluate cell apoptosis and survival-associated proteins, and the results demonstrated that DIOS treatment resulted in the activation of the p53-dependent apoptosis pathway.	diosmetin	126-130	tumor protein p53	Homo sapiens	175-178
28101238-6	2016	Our results revealed that DIOS caused inhibition of the nuclear factor (NF)-kappaB signaling pathway and downregulation of Notch3 receptor.	diosmetin	26-30	notch receptor 3	Homo sapiens	123-129
28101238-7	2016	Furthermore, by using small hairpin RNA-Notch3, it was confirmed that DIOS inhibited the NF-kappaB signaling pathway by inactivation of Notch3.	diosmetin	70-74	notch receptor 3	Homo sapiens	40-46
28101238-7	2016	Furthermore, by using small hairpin RNA-Notch3, it was confirmed that DIOS inhibited the NF-kappaB signaling pathway by inactivation of Notch3.	diosmetin	70-74	nuclear factor kappa B subunit 1	Homo sapiens	89-98
28101238-7	2016	Furthermore, by using small hairpin RNA-Notch3, it was confirmed that DIOS inhibited the NF-kappaB signaling pathway by inactivation of Notch3.	diosmetin	70-74	notch receptor 3	Homo sapiens	136-142
27725131-3	2016	Diosmetin, one major bioactive metabolite of diosmin, increased inhibitory GSK-3beta phosphorylation, while selectively reducing gamma-secretase activity, Abeta generation, tau hyperphosphorylation and pro-inflammatory activation of microglia in vitro, without altering Notch processing.	diosmetin	0-9	glycogen synthase kinase 3 beta	Mus musculus	75-84
27832172-0	2016	Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells.	diosmetin	34-43	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	113-119
27832172-2	2016	This study also investigated the effects of breast cancer resistance protein (BCRP) on the efflux of diosmetin and chrysoeriol glucuronides in HeLa cells overexpressing UGT1A9 (HeLa-UGT1A9).	diosmetin	101-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-82
27832172-5	2016	Importantly, in HeLa-UGT1A9, Ko143 significantly inhibited the efflux of diosmetin and chrysoeriol glucuronides and increased their intracellular levels in a dose-dependent manner.	diosmetin	73-82	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	16-27
27832172-6	2016	This observation suggested that BCRP-mediated excretion was the predominant pathway for diosmetin and chrysoeriol disposition.	diosmetin	88-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-36
27832172-7	2016	In conclusion, UGT1A1, UGT1A6, and UGT1A9 were the chief contributors to the regioselective glucuronidation of diosmetin and chrysoeriol in the liver.	diosmetin	111-120	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	15-21
27832172-7	2016	In conclusion, UGT1A1, UGT1A6, and UGT1A9 were the chief contributors to the regioselective glucuronidation of diosmetin and chrysoeriol in the liver.	diosmetin	111-120	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	23-29
27832172-7	2016	In conclusion, UGT1A1, UGT1A6, and UGT1A9 were the chief contributors to the regioselective glucuronidation of diosmetin and chrysoeriol in the liver.	diosmetin	111-120	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	35-41
27725131-3	2016	Diosmetin, one major bioactive metabolite of diosmin, increased inhibitory GSK-3beta phosphorylation, while selectively reducing gamma-secretase activity, Abeta generation, tau hyperphosphorylation and pro-inflammatory activation of microglia in vitro, without altering Notch processing.	diosmetin	0-9	amyloid beta (A4) precursor protein	Mus musculus	155-160
26569039-4	2016	Meanwhile, quercetin (7), diosmetin (9) and luteolin (10) inhibited TNF-alpha-induced NF-kappaB reporter gene expression on HeLa cells up to 30 and 100 muM.	diosmetin	26-35	tumor necrosis factor	Homo sapiens	68-77
26569039-4	2016	Meanwhile, quercetin (7), diosmetin (9) and luteolin (10) inhibited TNF-alpha-induced NF-kappaB reporter gene expression on HeLa cells up to 30 and 100 muM.	diosmetin	26-35	latexin	Homo sapiens	152-155
26021482-0	2015	Diosmetin inhibits the expression of alpha-hemolysin in Staphylococcus aureus.	diosmetin	0-9	AT695_RS11870	Staphylococcus aureus	37-52
27176768-3	2016	The present study observed that cell proliferation of HepG2 cells was inhibited by Dio treatment and tumor protein p53 was significantly increased following Dio treatment.	diosmetin	157-160	tumor protein p53	Homo sapiens	115-118
27176768-5	2016	These findings suggest a novel function for the TGF-beta/TGF-beta receptor signaling pathway and that it may be a key target of Dio-induced cell apoptosis in HepG2 cells.	diosmetin	128-131	transforming growth factor beta 1	Homo sapiens	48-56
26847170-0	2016	Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP-2 and MMP-9.	diosmetin	0-9	matrix metallopeptidase 2	Homo sapiens	111-116
26847170-0	2016	Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP-2 and MMP-9.	diosmetin	0-9	matrix metallopeptidase 9	Homo sapiens	121-126
26847170-10	2016	DIOS was observed to inhibit the metastasis of SK-HEP-1 and MHcc97H cells by downregulating the expression of MMP-2/9 via the PKC/MAPK/MMP pathways.	diosmetin	0-4	matrix metallopeptidase 2	Homo sapiens	110-115
27176768-0	2016	Diosmetin induces apoptosis by upregulating p53 via the TGF-beta signal pathway in HepG2 hepatoma cells.	diosmetin	0-9	tumor protein p53	Homo sapiens	44-47
27176768-0	2016	Diosmetin induces apoptosis by upregulating p53 via the TGF-beta signal pathway in HepG2 hepatoma cells.	diosmetin	0-9	transforming growth factor beta 1	Homo sapiens	56-64
27101925-0	2016	Diosmetin prevents TGF-beta1-induced epithelial-mesenchymal transition via ROS/MAPK signaling pathways.	diosmetin	0-9	transforming growth factor beta 1	Homo sapiens	19-28
27101925-3	2016	Herein, we investigated whether diosmetin inhibits transforming growth factor-beta1 (TGF-beta1)-induced EMT with underlying mechanisms in human bronchial epithelial (HBE) cells.	diosmetin	32-41	transforming growth factor beta 1	Homo sapiens	51-83
27101925-3	2016	Herein, we investigated whether diosmetin inhibits transforming growth factor-beta1 (TGF-beta1)-induced EMT with underlying mechanisms in human bronchial epithelial (HBE) cells.	diosmetin	32-41	transforming growth factor beta 1	Homo sapiens	85-94
27101925-8	2016	Diosmetin significantly suppressed TGF-beta1-induced increases in cell migration and altered N-cadherin, E-cadherin, and alpha-smooth muscle actin expression.	diosmetin	0-9	transforming growth factor beta 1	Homo sapiens	35-44
27101925-8	2016	Diosmetin significantly suppressed TGF-beta1-induced increases in cell migration and altered N-cadherin, E-cadherin, and alpha-smooth muscle actin expression.	diosmetin	0-9	cadherin 2	Homo sapiens	93-103
27101925-8	2016	Diosmetin significantly suppressed TGF-beta1-induced increases in cell migration and altered N-cadherin, E-cadherin, and alpha-smooth muscle actin expression.	diosmetin	0-9	cadherin 1	Homo sapiens	105-115
27101925-9	2016	In addition, diosmetin prevented TGF-beta1-induced intracellular ROS generation, down-regulated NOX4, and up-regulated SOD and catalase expression.	diosmetin	13-22	transforming growth factor beta 1	Homo sapiens	33-42
27101925-9	2016	In addition, diosmetin prevented TGF-beta1-induced intracellular ROS generation, down-regulated NOX4, and up-regulated SOD and catalase expression.	diosmetin	13-22	NADPH oxidase 4	Homo sapiens	96-100
27101925-9	2016	In addition, diosmetin prevented TGF-beta1-induced intracellular ROS generation, down-regulated NOX4, and up-regulated SOD and catalase expression.	diosmetin	13-22	catalase	Homo sapiens	127-135
27101925-10	2016	Furthermore, diosmetin remarkably inhibited TGF-beta1-induced phosphorylation of phosphoinositide 3-kinase (PI3K)/Akt and mitogen activated protein kinase (MAPK) pathways in HBE cells.	diosmetin	13-22	transforming growth factor beta 1	Homo sapiens	44-53
27101925-10	2016	Furthermore, diosmetin remarkably inhibited TGF-beta1-induced phosphorylation of phosphoinositide 3-kinase (PI3K)/Akt and mitogen activated protein kinase (MAPK) pathways in HBE cells.	diosmetin	13-22	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	81-106
27101925-10	2016	Furthermore, diosmetin remarkably inhibited TGF-beta1-induced phosphorylation of phosphoinositide 3-kinase (PI3K)/Akt and mitogen activated protein kinase (MAPK) pathways in HBE cells.	diosmetin	13-22	AKT serine/threonine kinase 1	Homo sapiens	114-117
27101925-11	2016	SIGNIFICANCE: Our results demonstrate for the first time that diosmetin alleviates TGF-beta1-induced EMT by inhibiting ROS generation and inactivating PI3K/Akt and MAPK pathways.	diosmetin	62-71	transforming growth factor beta 1	Homo sapiens	83-92
27101925-11	2016	SIGNIFICANCE: Our results demonstrate for the first time that diosmetin alleviates TGF-beta1-induced EMT by inhibiting ROS generation and inactivating PI3K/Akt and MAPK pathways.	diosmetin	62-71	AKT serine/threonine kinase 1	Homo sapiens	156-159
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	lipase, endothelial	Mus musculus	78-84
26033789-7	2015	Matrix metallopeptidase-9, transforming growth factor-beta1, and vascular endothelial growth factor levels were also alleviated by diosmetin, suggesting that the remission of airway remodeling might be attributed to the decline of these proteins.	diosmetin	131-140	matrix metallopeptidase 9	Mus musculus	0-59
25075433-4	2014	Diosmetin could significantly restore AAPH-induced increase of intracelluar antioxidant enzyme (SOD, GPx, and CAT) activities to normal levels, as well as inhibit intracellular malondialdehyde (MDA) formation.	diosmetin	0-9	catalase	Homo sapiens	110-113
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	myeloperoxidase	Mus musculus	214-217
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	nitric oxide synthase 2, inducible	Mus musculus	291-322
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	nitric oxide synthase 2, inducible	Mus musculus	324-328
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	339-365
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	tumor necrosis factor	Mus musculus	128-161
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	interleukin 1 beta	Mus musculus	163-185
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	interleukin 6	Mus musculus	191-195
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	myeloperoxidase	Mus musculus	197-212
23709168-7	2014	Among the active flavonoids, diosmetin was found to inhibit SCF-induced melanogenesis in a human melanoderm model.	diosmetin	29-38	KIT ligand	Homo sapiens	60-63
23709168-8	2014	These results strongly suggest that C. morifolium extract and diosmetin have potential to suppress SCF-/UVB-induced melanogenesis, and could be developed as anti-pigmentation agents.	diosmetin	62-71	KIT ligand	Homo sapiens	99-102
23541215-0	2013	Synergistic effects of diosmetin with erythromycin against ABC transporter over-expressed methicillin-resistant Staphylococcus aureus (MRSA) RN4220/pUL5054 and inhibition of MRSA pyruvate kinase.	diosmetin	23-32	ABC transporter	Staphylococcus aureus	59-74
23541215-0	2013	Synergistic effects of diosmetin with erythromycin against ABC transporter over-expressed methicillin-resistant Staphylococcus aureus (MRSA) RN4220/pUL5054 and inhibition of MRSA pyruvate kinase.	diosmetin	23-32	AT695_RS09030	Staphylococcus aureus	179-194
23541215-5	2013	The aim of this study was to investigate whether diosmin and diosmetin could inhibit the growth of MRSA and the in vitro enzymatic activity of a newly discovered MRSA drug target, pyruvate kinase (PK).	diosmetin	61-70	AT695_RS09030	Staphylococcus aureus	180-195
23541215-5	2013	The aim of this study was to investigate whether diosmin and diosmetin could inhibit the growth of MRSA and the in vitro enzymatic activity of a newly discovered MRSA drug target, pyruvate kinase (PK).	diosmetin	61-70	AT695_RS09030	Staphylococcus aureus	197-199
22353148-0	2012	Probing the binding of the flavonoid diosmetin to human serum albumin by multispectroscopic techniques.	diosmetin	37-46	albumin	Homo sapiens	56-69
22749133-0	2013	The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.	diosmetin	15-24	mitogen-activated protein kinase 8	Homo sapiens	151-154
22749133-0	2013	The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.	diosmetin	15-24	mitogen-activated protein kinase 1	Homo sapiens	159-162
22749133-0	2013	The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.	diosmetin	15-24	tumor protein p53	Homo sapiens	167-174
22749133-2	2013	The present study aimed to characterize the metabolism and further antiproliferative activity of the natural flavonoid diosmetin in the CYP1-expressing human hepatoma cell line HepG2.	diosmetin	119-128	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	136-140
22999990-3	2012	Luteolin and apigenin are two main bioactive components in Flos Chrysanthemi, and chrysoeriol and diosmetin are two methylated metabolites of luteolin in vivo by cathechol-O-methyltransferase (COMT).	diosmetin	98-107	catechol-O-methyltransferase	Rattus norvegicus	162-191
22999990-3	2012	Luteolin and apigenin are two main bioactive components in Flos Chrysanthemi, and chrysoeriol and diosmetin are two methylated metabolites of luteolin in vivo by cathechol-O-methyltransferase (COMT).	diosmetin	98-107	catechol-O-methyltransferase	Rattus norvegicus	193-197
22353148-1	2012	The binding mechanism of molecular interaction between diosmetin and human serum albumin (HSA) in a pH 7.4 phosphate buffer was studied using atomic force microscopy (AFM) and various spectroscopic techniques including fluorescence, resonance light scattering (RLS), UV-vis absorption, circular dichroism (CD), and Fourier transform infrared (FT-IR) spectroscopy.	diosmetin	55-64	albumin	Homo sapiens	75-88
22022544-6	2011	Conversely, mono-methyl-flavonoids, such as diosmetin (4"-O-metlylluteolin), efficiently inhibited SIK2 and promoted melanogenesis in this cell line.	diosmetin	44-53	salt inducible kinase 2	Mus musculus	99-103
21851214-0	2011	Protective effects of diosmetin extracted from Galium verum L. on the thymus of U14-bearing mice.	diosmetin	22-31	small nucleolar RNA, C/D box 14A	Mus musculus	80-83
21482471-5	2011	The most potent inhibitors of CYP1-EROD activity were the methoxylated flavones acacetin, diosmetin, eupatorin and the di-hydroxylated flavone chrysin, indicating that the 4"-OCH(3) group at the B ring and the 5,7-dihydroxy motif at the A ring play a prominent role in EROD inhibition.	diosmetin	90-99	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	30-34
21791871-0	2011	Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin.	diosmetin	76-85	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	14-33
21791871-1	2011	The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6alpha-hydroxy-paclitaxel as a probe reaction.	diosmetin	51-60	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	134-140
21791871-6	2011	The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site.	diosmetin	139-148	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	168-174
21791871-7	2011	The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co-administered drugs metabolized by this CYP.	diosmetin	23-32	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	42-48
18269307-0	2008	Diosmetin induces human osteoblastic differentiation through the protein kinase C/p38 and extracellular signal-regulated kinase 1/2 pathway.	diosmetin	0-9	mitogen-activated protein kinase 1	Homo sapiens	82-85
20877134-0	2010	Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro.	diosmetin	11-20	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-80
20877134-1	2010	The aim of this study was to examine in vitro, by means of kinetic analysis and molecular docking simulations, the effects of the flavone diosmetin and its flavanone analog hesperetin on CYP (cytochrome P450) 2C9-mediated drug metabolism.	diosmetin	138-147	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	192-212
20877134-6	2010	The results of molecular docking simulations were consistent with those of kinetic analysis, since they showed that the putative binding sites of both diosmetin and hesperetin coincided with the CYP2C9 substrate binding site.	diosmetin	151-160	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	195-201
20877134-7	2010	The demonstration that diosmetin and hesperetin inhibit CYP2C9-mediated diclofenac metabolism at low micromolar concentrations is of potential clinical relevance because CYP2C9 is responsible for the biotransformation of various therapeutically important drugs that have narrow therapeutic indexes.	diosmetin	23-32	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	56-62
20877134-7	2010	The demonstration that diosmetin and hesperetin inhibit CYP2C9-mediated diclofenac metabolism at low micromolar concentrations is of potential clinical relevance because CYP2C9 is responsible for the biotransformation of various therapeutically important drugs that have narrow therapeutic indexes.	diosmetin	23-32	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	170-176
18976853-0	2009	Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450.	diosmetin	35-44	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	48-52
18976853-0	2009	Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450.	diosmetin	35-44	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-69
18976853-3	2009	In this study we investigated the anticancer activity of the flavonoid diosmetin, as a result of cytochrome P450 CYP1 metabolism.	diosmetin	71-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	108-112
18976853-3	2009	In this study we investigated the anticancer activity of the flavonoid diosmetin, as a result of cytochrome P450 CYP1 metabolism.	diosmetin	71-80	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	113-117
18976853-4	2009	Diosmetin was metabolized to luteolin via an aromatic demethylation reaction on the B-ring from CYP1A1, CYP1B1 and the hepatic isozyme CYP1A2.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	96-102
18976853-4	2009	Diosmetin was metabolized to luteolin via an aromatic demethylation reaction on the B-ring from CYP1A1, CYP1B1 and the hepatic isozyme CYP1A2.	diosmetin	0-9	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	104-110
18976853-4	2009	Diosmetin was metabolized to luteolin via an aromatic demethylation reaction on the B-ring from CYP1A1, CYP1B1 and the hepatic isozyme CYP1A2.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	135-141
18976853-7	2009	Diosmetin was also metabolized to luteolin in estrogen receptor positive breast cell-line (MCF-7 cells) preinduced for 24 h with the potent CYP1 inducer 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	140-144
18976853-9	2009	Taken together these data suggest that the flavonoid diosmetin is metabolised to the more active molecule luteolin by CYP1 family enzymes.	diosmetin	53-62	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	118-122
18590707-6	2008	Inducible nitric oxide synthase expression was also blocked largely by some flavonoids, especially quercetin, luteolin and apigenin, while cyclooxygenase 2 was downregulated only by apigenin, diosmetin and quercetin.	diosmetin	192-201	nitric oxide synthase 2	Rattus norvegicus	0-31
18590707-6	2008	Inducible nitric oxide synthase expression was also blocked largely by some flavonoids, especially quercetin, luteolin and apigenin, while cyclooxygenase 2 was downregulated only by apigenin, diosmetin and quercetin.	diosmetin	192-201	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	139-155
19424633-0	2009	Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation.	diosmetin	36-45	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	131-135
19424633-5	2009	We suggest that diosmetin exerts cytostatic effects in MDA-MB 468 cells, due to CYP1A1 and CYP1B1 catalyzed conversion to the flavone luteolin.	diosmetin	16-25	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	80-86
19424633-5	2009	We suggest that diosmetin exerts cytostatic effects in MDA-MB 468 cells, due to CYP1A1 and CYP1B1 catalyzed conversion to the flavone luteolin.	diosmetin	16-25	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	91-97
18269307-0	2008	Diosmetin induces human osteoblastic differentiation through the protein kinase C/p38 and extracellular signal-regulated kinase 1/2 pathway.	diosmetin	0-9	mitogen-activated protein kinase 1	Homo sapiens	90-129
18269307-7	2008	RESULTS: Diosmetin exhibited an effect on osteoblastic maturation and differentiation by means of ALP activity, osteocalcin, osteopontin, and type I collagen production, as well as Runx2 upregulation.	diosmetin	9-18	alkaline phosphatase, placental	Homo sapiens	98-101
18269307-7	2008	RESULTS: Diosmetin exhibited an effect on osteoblastic maturation and differentiation by means of ALP activity, osteocalcin, osteopontin, and type I collagen production, as well as Runx2 upregulation.	diosmetin	9-18	bone gamma-carboxyglutamate protein	Homo sapiens	112-123
18269307-7	2008	RESULTS: Diosmetin exhibited an effect on osteoblastic maturation and differentiation by means of ALP activity, osteocalcin, osteopontin, and type I collagen production, as well as Runx2 upregulation.	diosmetin	9-18	secreted phosphoprotein 1	Homo sapiens	125-136
18269307-7	2008	RESULTS: Diosmetin exhibited an effect on osteoblastic maturation and differentiation by means of ALP activity, osteocalcin, osteopontin, and type I collagen production, as well as Runx2 upregulation.	diosmetin	9-18	RUNX family transcription factor 2	Homo sapiens	181-186
18269307-8	2008	Induction of differentiation by diosmetin was associated with increased PKCdelta phosphorylation and the activations of Rac1 and p38 and ERK1/2 kinases.	diosmetin	32-41	protein kinase C delta	Homo sapiens	72-80
18269307-8	2008	Induction of differentiation by diosmetin was associated with increased PKCdelta phosphorylation and the activations of Rac1 and p38 and ERK1/2 kinases.	diosmetin	32-41	Rac family small GTPase 1	Homo sapiens	120-124
18269307-8	2008	Induction of differentiation by diosmetin was associated with increased PKCdelta phosphorylation and the activations of Rac1 and p38 and ERK1/2 kinases.	diosmetin	32-41	mitogen-activated protein kinase 1	Homo sapiens	129-132
18269307-8	2008	Induction of differentiation by diosmetin was associated with increased PKCdelta phosphorylation and the activations of Rac1 and p38 and ERK1/2 kinases.	diosmetin	32-41	mitogen-activated protein kinase 3	Homo sapiens	137-143
18269307-10	2008	In addition, blocking p38 and ERK1/2 by siRNA transfection also suppressed diosmetin-induced cell differentiation.	diosmetin	75-84	mitogen-activated protein kinase 1	Homo sapiens	22-25
18269307-10	2008	In addition, blocking p38 and ERK1/2 by siRNA transfection also suppressed diosmetin-induced cell differentiation.	diosmetin	75-84	mitogen-activated protein kinase 3	Homo sapiens	30-36
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	protein kinase C delta	Homo sapiens	100-108
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	Rac family small GTPase 1	Homo sapiens	109-113
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	mitogen-activated protein kinase kinase 3	Homo sapiens	114-118
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	mitogen-activated protein kinase 1	Homo sapiens	121-124
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	protein kinase C delta	Homo sapiens	129-137
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	Rac family small GTPase 1	Homo sapiens	138-142
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	mitogen-activated protein kinase kinase 1	Homo sapiens	143-149
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	mitogen-activated protein kinase 3	Homo sapiens	151-157
18269307-11	2008	CONCLUSIONS: In this study, we show that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.	diosmetin	41-50	RUNX family transcription factor 2	Homo sapiens	158-163
12150856-4	2002	In addition, several flavonoids, that is apigenin, luteolin, diosmetin, fisetin, and quercetin, inhibited the antigen-IgE-mediated TNF-alpha and IL-4 production from RBL-2H3 cells, both of which participate in the late phase of type I allergic reactions.	diosmetin	61-70	tumor necrosis factor	Rattus norvegicus	131-140
18191104-3	2008	Both diosmetin and luteolin decreased 1"-OH-MDZ formation by human recombinant CYP3A4, but not CYP3A5, whereas they decreased 4-OH-MDZ formation by both recombinant enzymes.	diosmetin	5-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
18191104-7	2008	The results of the study may be of clinical relevance since they suggest that luteolin and diosmetin may cause pharmacokinetic interactions with co-administered drugs metabolized via CYP3A.	diosmetin	91-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	183-188
18191104-0	2008	Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes.	diosmetin	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-112
18191104-0	2008	Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes.	diosmetin	11-20	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	117-123
12150856-4	2002	In addition, several flavonoids, that is apigenin, luteolin, diosmetin, fisetin, and quercetin, inhibited the antigen-IgE-mediated TNF-alpha and IL-4 production from RBL-2H3 cells, both of which participate in the late phase of type I allergic reactions.	diosmetin	61-70	interleukin 4	Rattus norvegicus	145-149
10781868-2	2000	The flavones acacetin and diosmetin were potent inhibitors of ethoxyresorufin O-dealkylase (EROD) activity of CYP1A and CYP1B1.	diosmetin	26-35	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	120-126
34682865-0	2021	Diosmetin Induces Modulation of Igf-1 and Il-6 Levels to Alter Rictor-Akt-PKCalpha Cascade in Inhibition of Prostate Cancer.	diosmetin	0-9	insulin like growth factor 1	Homo sapiens	32-37
9661887-0	1998	Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity.	diosmetin	12-21	aryl hydrocarbon receptor	Homo sapiens	42-67
9661887-0	1998	Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity.	diosmetin	12-21	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	95-114
9661887-1	1998	We investigated the effect of the chemopreventive compound diosmin and its aglycone form, diosmetin, on the carcinogen activation pathway mediated by the aryl hydrocarbon receptor (AhR) in MCF-7 human breast epithelial cancer cells.	diosmetin	90-99	aryl hydrocarbon receptor	Homo sapiens	154-179
9661887-1	1998	We investigated the effect of the chemopreventive compound diosmin and its aglycone form, diosmetin, on the carcinogen activation pathway mediated by the aryl hydrocarbon receptor (AhR) in MCF-7 human breast epithelial cancer cells.	diosmetin	90-99	aryl hydrocarbon receptor	Homo sapiens	181-184
9661887-4	1998	Diosmetin, but not diosmin, directly inhibited cytochrome P450 1A1 (CYP1A1) activity in a noncompetitive manner in microsomes isolated from DMBA-treated cells, as assayed by ethyoxyresorufin-O-deethylase activity.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	47-66
9661887-4	1998	Diosmetin, but not diosmin, directly inhibited cytochrome P450 1A1 (CYP1A1) activity in a noncompetitive manner in microsomes isolated from DMBA-treated cells, as assayed by ethyoxyresorufin-O-deethylase activity.	diosmetin	0-9	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	68-74
9661887-5	1998	Treatment of the cells with diosmin or diosmetin, on the other hand, caused a dose- and time-dependent increase in CYP1A1 activity in intact cells that was comparable to that induced by DMBA or by the aryl hydrocarbon benzo(a)pyrene.	diosmetin	39-48	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	115-121
9661887-6	1998	Both diosmin and diosmetin caused an increase in the transcription of the CYP1A1 gene, as measured by increased levels of CYP1A1 mRNA.	diosmetin	17-26	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	74-80
9661887-6	1998	Both diosmin and diosmetin caused an increase in the transcription of the CYP1A1 gene, as measured by increased levels of CYP1A1 mRNA.	diosmetin	17-26	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	122-128
9661887-8	1998	These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation.	diosmetin	40-49	aryl hydrocarbon receptor	Homo sapiens	86-89
9661887-8	1998	These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation.	diosmetin	40-49	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	120-126
9661887-8	1998	These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation.	diosmetin	40-49	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	145-151
9661887-8	1998	These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation.	diosmetin	40-49	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	145-151
9661887-8	1998	These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation.	diosmetin	176-185	aryl hydrocarbon receptor	Homo sapiens	86-89
33811596-0	2021	Diosmetin induces apoptosis in ovarian cancer cells by activating reactive oxygen species and inhibiting the Nrf2 pathway.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	109-113
33811596-5	2021	Moreover, Dio upregulated the levels of Bax and cleaved Caspase-3 and PARP while downregulating the level of Bcl2.	diosmetin	10-13	BCL2 associated X, apoptosis regulator	Homo sapiens	40-43
33811596-5	2021	Moreover, Dio upregulated the levels of Bax and cleaved Caspase-3 and PARP while downregulating the level of Bcl2.	diosmetin	10-13	caspase 3	Homo sapiens	56-65
33811596-5	2021	Moreover, Dio upregulated the levels of Bax and cleaved Caspase-3 and PARP while downregulating the level of Bcl2.	diosmetin	10-13	collagen type XI alpha 2 chain	Homo sapiens	70-74
33811596-5	2021	Moreover, Dio upregulated the levels of Bax and cleaved Caspase-3 and PARP while downregulating the level of Bcl2.	diosmetin	10-13	BCL2 apoptosis regulator	Homo sapiens	109-113
33811596-6	2021	Mechanistically, our results revealed that Dio inhibited Nrf2 and induced the production of reactive oxygen species (ROS).	diosmetin	43-46	NFE2 like bZIP transcription factor 2	Homo sapiens	57-61
33811596-8	2021	Additionally, overexpression of Nrf2 partially suppressed the Dio-induced apoptosis and proliferation inhibition in these cells.	diosmetin	62-65	NFE2 like bZIP transcription factor 2	Homo sapiens	32-36
33811596-9	2021	These findings indicate that Dio exerts an anti-tumor activity by upregulating ROS levels and inhibiting Nrf2, indicating that Dio is a promising chemotherapeutic candidate for the treatment of ovarian cancer.	diosmetin	29-32	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
33811596-9	2021	These findings indicate that Dio exerts an anti-tumor activity by upregulating ROS levels and inhibiting Nrf2, indicating that Dio is a promising chemotherapeutic candidate for the treatment of ovarian cancer.	diosmetin	127-130	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
34922636-6	2021	Moreover, Diosmetin downregulated the expression of anti-apoptotic protein Bcl-xL while upregulated the levels of pro-apoptotic proteins including cleaved Caspase-3, cleaved-PARP and Bax.	diosmetin	10-19	BCL2 associated X, apoptosis regulator	Homo sapiens	183-186
34922636-0	2021	Diosmetin inhibits cell proliferation and promotes apoptosis through STAT3/c-Myc signaling pathway in human osteosarcoma cells.	diosmetin	0-9	signal transducer and activator of transcription 3	Homo sapiens	69-74
34922636-0	2021	Diosmetin inhibits cell proliferation and promotes apoptosis through STAT3/c-Myc signaling pathway in human osteosarcoma cells.	diosmetin	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	75-80
34922636-6	2021	Moreover, Diosmetin downregulated the expression of anti-apoptotic protein Bcl-xL while upregulated the levels of pro-apoptotic proteins including cleaved Caspase-3, cleaved-PARP and Bax.	diosmetin	10-19	BCL2 like 1	Homo sapiens	75-81
34922636-6	2021	Moreover, Diosmetin downregulated the expression of anti-apoptotic protein Bcl-xL while upregulated the levels of pro-apoptotic proteins including cleaved Caspase-3, cleaved-PARP and Bax.	diosmetin	10-19	caspase 3	Homo sapiens	155-164
34922636-6	2021	Moreover, Diosmetin downregulated the expression of anti-apoptotic protein Bcl-xL while upregulated the levels of pro-apoptotic proteins including cleaved Caspase-3, cleaved-PARP and Bax.	diosmetin	10-19	poly(ADP-ribose) polymerase 1	Homo sapiens	174-178
34922636-7	2021	Furthermore, diosmetin dose-dependently inhibited STAT3 phosphorylation, reduced the expression of its downstream protein c-Myc and impeded the interaction between STAT3 molecules.	diosmetin	13-22	signal transducer and activator of transcription 3	Homo sapiens	50-55
34922636-7	2021	Furthermore, diosmetin dose-dependently inhibited STAT3 phosphorylation, reduced the expression of its downstream protein c-Myc and impeded the interaction between STAT3 molecules.	diosmetin	13-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	122-127
34922636-7	2021	Furthermore, diosmetin dose-dependently inhibited STAT3 phosphorylation, reduced the expression of its downstream protein c-Myc and impeded the interaction between STAT3 molecules.	diosmetin	13-22	signal transducer and activator of transcription 3	Homo sapiens	164-169
34922636-8	2021	CONCLUSIONS: These results suggest that diosmetin exerts anti-osteosarcoma effects by suppressing cell proliferation and inducing apoptosis via inhibiting the activation of STAT3/c-Myc signaling pathway, which provide the possibility for diosmetin to be a chemotherapeutic candidate for osteosarcoma.	diosmetin	40-49	signal transducer and activator of transcription 3	Homo sapiens	173-178
34922636-8	2021	CONCLUSIONS: These results suggest that diosmetin exerts anti-osteosarcoma effects by suppressing cell proliferation and inducing apoptosis via inhibiting the activation of STAT3/c-Myc signaling pathway, which provide the possibility for diosmetin to be a chemotherapeutic candidate for osteosarcoma.	diosmetin	40-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	179-184
34950037-8	2021	In vitro, Quercetin, Methyl rosmarinate, Kaempferol, Diosmetin and Acacetin were demonstrated to retard podocyte proliferation by inhibiting DPP4 activity and were the top five compounds predicted by molecular docking to be the most likely to affect DPP4 activity.	diosmetin	53-62	dipeptidylpeptidase 4	Mus musculus	141-145
34950037-8	2021	In vitro, Quercetin, Methyl rosmarinate, Kaempferol, Diosmetin and Acacetin were demonstrated to retard podocyte proliferation by inhibiting DPP4 activity and were the top five compounds predicted by molecular docking to be the most likely to affect DPP4 activity.	diosmetin	53-62	dipeptidylpeptidase 4	Mus musculus	250-254
34713558-0	2022	Diosmetin inhibits apoptosis and activates AMPK-induced autophagy in myocardial damage under hypoxia environment.	diosmetin	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	43-47
34713558-6	2022	Furthermore, DIOS induced AMP-activated protein kinase (AMPK) activation and Compound C (5 muM), an AMPK inhibitor, attenuated the inhibition of DIOS on the apoptosis of cardiomyocytes under hypoxia environment.	diosmetin	13-17	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	26-54
34713558-6	2022	Furthermore, DIOS induced AMP-activated protein kinase (AMPK) activation and Compound C (5 muM), an AMPK inhibitor, attenuated the inhibition of DIOS on the apoptosis of cardiomyocytes under hypoxia environment.	diosmetin	13-17	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	56-60
34713558-6	2022	Furthermore, DIOS induced AMP-activated protein kinase (AMPK) activation and Compound C (5 muM), an AMPK inhibitor, attenuated the inhibition of DIOS on the apoptosis of cardiomyocytes under hypoxia environment.	diosmetin	145-149	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	100-104
34713558-8	2022	Our findings indicated that DIOS alleviated hypoxia-induced myocardial apoptosis via inducing the activation of AMPK-induced autophagy.	diosmetin	28-32	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	112-116
34713558-9	2022	In summary, the study suggested that DIOS inhibited the apoptosis and induced the autophagy of hypoxia-induced cardiomyocytes through AMPK activation.	diosmetin	37-41	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	134-138
34682865-13	2021	Furthermore, the Bax/Bcl-2 expression ratio was increased in response to diosmetin treatment, which would result in increased apoptosis.	diosmetin	73-82	BCL2 associated X, apoptosis regulator	Homo sapiens	17-20
34682865-13	2021	Furthermore, the Bax/Bcl-2 expression ratio was increased in response to diosmetin treatment, which would result in increased apoptosis.	diosmetin	73-82	BCL2 apoptosis regulator	Homo sapiens	21-26
34682865-0	2021	Diosmetin Induces Modulation of Igf-1 and Il-6 Levels to Alter Rictor-Akt-PKCalpha Cascade in Inhibition of Prostate Cancer.	diosmetin	0-9	interleukin 6	Homo sapiens	42-46
34682865-0	2021	Diosmetin Induces Modulation of Igf-1 and Il-6 Levels to Alter Rictor-Akt-PKCalpha Cascade in Inhibition of Prostate Cancer.	diosmetin	0-9	RPTOR independent companion of MTOR complex 2	Homo sapiens	63-69
34682865-0	2021	Diosmetin Induces Modulation of Igf-1 and Il-6 Levels to Alter Rictor-Akt-PKCalpha Cascade in Inhibition of Prostate Cancer.	diosmetin	0-9	AKT serine/threonine kinase 1	Homo sapiens	70-73
34682865-0	2021	Diosmetin Induces Modulation of Igf-1 and Il-6 Levels to Alter Rictor-Akt-PKCalpha Cascade in Inhibition of Prostate Cancer.	diosmetin	0-9	protein kinase C alpha	Homo sapiens	74-82
34682865-11	2021	Subsequently, it was found that diosmetin, a natural plant aglycone, had the potential to modulate the downstream signaling cascade of Rictor/AKT/PKCalpha to inhibit the progression of prostate cancer.	diosmetin	32-41	RPTOR independent companion of MTOR complex 2	Homo sapiens	135-141
34682865-11	2021	Subsequently, it was found that diosmetin, a natural plant aglycone, had the potential to modulate the downstream signaling cascade of Rictor/AKT/PKCalpha to inhibit the progression of prostate cancer.	diosmetin	32-41	AKT serine/threonine kinase 1	Homo sapiens	142-145
34682865-11	2021	Subsequently, it was found that diosmetin, a natural plant aglycone, had the potential to modulate the downstream signaling cascade of Rictor/AKT/PKCalpha to inhibit the progression of prostate cancer.	diosmetin	32-41	protein kinase C alpha	Homo sapiens	146-154
34682865-12	2021	Treatment of LNCaP and PC-3 cells with diosmetin inhibited the phosphorylation of Rictor (Thr-1135), AKT (Ser-473) and PKCalpha (Ser-657) in a dose-dependent manner.	diosmetin	39-48	RPTOR independent companion of MTOR complex 2	Homo sapiens	82-88
34682865-12	2021	Treatment of LNCaP and PC-3 cells with diosmetin inhibited the phosphorylation of Rictor (Thr-1135), AKT (Ser-473) and PKCalpha (Ser-657) in a dose-dependent manner.	diosmetin	39-48	AKT serine/threonine kinase 1	Homo sapiens	101-104
34682865-12	2021	Treatment of LNCaP and PC-3 cells with diosmetin inhibited the phosphorylation of Rictor (Thr-1135), AKT (Ser-473) and PKCalpha (Ser-657) in a dose-dependent manner.	diosmetin	39-48	protein kinase C alpha	Homo sapiens	119-127
34573119-0	2021	Diosmetin Ameliorates Vascular Dysfunction and Remodeling by Modulation of Nrf2/HO-1 and p-JNK/p-NF-kappaB Expression in Hypertensive Rats.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	75-79
34576189-9	2021	MGO-derived AGE formation was inhibited the most by hesperetin, and GO-derived AGEs by diosmetin.	diosmetin	87-96	renin binding protein	Homo sapiens	12-15
34573119-0	2021	Diosmetin Ameliorates Vascular Dysfunction and Remodeling by Modulation of Nrf2/HO-1 and p-JNK/p-NF-kappaB Expression in Hypertensive Rats.	diosmetin	0-9	heme oxygenase 1	Rattus norvegicus	80-84
34573119-0	2021	Diosmetin Ameliorates Vascular Dysfunction and Remodeling by Modulation of Nrf2/HO-1 and p-JNK/p-NF-kappaB Expression in Hypertensive Rats.	diosmetin	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	91-94
34573119-5	2021	Increases in plasma and aortic tissue malondialdehyde (MDA) and carotid superoxide generations and reductions of plasma superoxide dismutase, catalase, and nitric oxide in hypertensive rats were ameliorated by diosmetin (p < 0.05).	diosmetin	210-219	catalase	Rattus norvegicus	142-150
34573119-6	2021	Diosmetin increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in hypertensive rats.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	46-89
34573119-6	2021	Diosmetin increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in hypertensive rats.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	91-95
34573119-6	2021	Diosmetin increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in hypertensive rats.	diosmetin	0-9	heme oxygenase 1	Rattus norvegicus	101-117
34573119-6	2021	Diosmetin increased the protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in hypertensive rats.	diosmetin	0-9	heme oxygenase 1	Rattus norvegicus	119-123
34278965-5	2021	Among all the experimental compounds, diosmetin has shown the best docking values against the Mpro of SARS-CoV-2 compared to the standard antiviral drug.	diosmetin	38-47	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	94-98
34278965-9	2021	Considering molecular docking, simulation, and DFT analysis of the selected compounds, notably eriodictoyl, quercetin, and diosmetin showed good potential against SARS-CoV-2 Mpro.	diosmetin	123-132	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	174-178
34262136-11	2022	Diosmetin reversed the effects of si-circSirt1 and si-Sirt1 in LPS-treated Caco-2 and IEC-6 cells.	diosmetin	0-9	sirtuin 1	Homo sapiens	54-59
34262136-13	2022	Our results have linked colitis to the circ-Sirt1/Sirt1 signaling pathway, which is activated by diosmetin.	diosmetin	97-106	sirtuin 1	Mus musculus	44-49
34262136-13	2022	Our results have linked colitis to the circ-Sirt1/Sirt1 signaling pathway, which is activated by diosmetin.	diosmetin	97-106	sirtuin 1	Mus musculus	50-55
34262136-0	2022	Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis.	diosmetin	0-9	sirtuin 1	Mus musculus	121-126
34262136-0	2022	Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis.	diosmetin	0-9	sirtuin 1	Mus musculus	127-132
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	occludin	Mus musculus	192-200
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	claudin 1	Mus musculus	202-211
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	interleukin 1 alpha	Mus musculus	293-301
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	interleukin 6	Mus musculus	303-307
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	tumor necrosis factor	Mus musculus	309-318
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	cytochrome c oxidase II, mitochondrial	Mus musculus	324-329
34262136-10	2022	Furthermore, we demonstrated that diosmetin markedly increased the expression of Nrf2 and HO-1 and reduced the ratio of acetylated NF-kappaB and NF-kappaB by activating the circ-Sirt1/Sirt1 axis, which inhibited oxidative stress and inflammation in vivo and in vitro.	diosmetin	34-43	nuclear factor, erythroid derived 2, like 2	Mus musculus	81-85
34262136-10	2022	Furthermore, we demonstrated that diosmetin markedly increased the expression of Nrf2 and HO-1 and reduced the ratio of acetylated NF-kappaB and NF-kappaB by activating the circ-Sirt1/Sirt1 axis, which inhibited oxidative stress and inflammation in vivo and in vitro.	diosmetin	34-43	heme oxygenase 1	Mus musculus	90-94
34262136-10	2022	Furthermore, we demonstrated that diosmetin markedly increased the expression of Nrf2 and HO-1 and reduced the ratio of acetylated NF-kappaB and NF-kappaB by activating the circ-Sirt1/Sirt1 axis, which inhibited oxidative stress and inflammation in vivo and in vitro.	diosmetin	34-43	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	131-140
34262136-10	2022	Furthermore, we demonstrated that diosmetin markedly increased the expression of Nrf2 and HO-1 and reduced the ratio of acetylated NF-kappaB and NF-kappaB by activating the circ-Sirt1/Sirt1 axis, which inhibited oxidative stress and inflammation in vivo and in vitro.	diosmetin	34-43	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	145-154
34262136-10	2022	Furthermore, we demonstrated that diosmetin markedly increased the expression of Nrf2 and HO-1 and reduced the ratio of acetylated NF-kappaB and NF-kappaB by activating the circ-Sirt1/Sirt1 axis, which inhibited oxidative stress and inflammation in vivo and in vitro.	diosmetin	34-43	sirtuin 1	Rattus norvegicus	178-183
34262136-10	2022	Furthermore, we demonstrated that diosmetin markedly increased the expression of Nrf2 and HO-1 and reduced the ratio of acetylated NF-kappaB and NF-kappaB by activating the circ-Sirt1/Sirt1 axis, which inhibited oxidative stress and inflammation in vivo and in vitro.	diosmetin	34-43	sirtuin 1	Rattus norvegicus	184-189
34091150-0	2021	Diosmetin ameliorate type 2 diabetic mellitus by up-regulating Corynebacterium glutamicum to regulate IRS/PI3K/AKT-mediated glucose metabolism disorder in KK-Ay mice.	diosmetin	0-9	isoleucine-tRNA synthetase	Mus musculus	102-105
34091150-0	2021	Diosmetin ameliorate type 2 diabetic mellitus by up-regulating Corynebacterium glutamicum to regulate IRS/PI3K/AKT-mediated glucose metabolism disorder in KK-Ay mice.	diosmetin	0-9	thymoma viral proto-oncogene 1	Mus musculus	111-114
34091150-11	2021	Moreover, treatment with C. glu and Dios together could markedly ameliorate glucose metabolism by up-regulating IRS/PI3K/AKT signaling pathway to promote glycogen synthesis and GLUT4 translocation.	diosmetin	36-40	isoleucine-tRNA synthetase	Mus musculus	112-115
34091150-11	2021	Moreover, treatment with C. glu and Dios together could markedly ameliorate glucose metabolism by up-regulating IRS/PI3K/AKT signaling pathway to promote glycogen synthesis and GLUT4 translocation.	diosmetin	36-40	thymoma viral proto-oncogene 1	Mus musculus	121-124
34091150-11	2021	Moreover, treatment with C. glu and Dios together could markedly ameliorate glucose metabolism by up-regulating IRS/PI3K/AKT signaling pathway to promote glycogen synthesis and GLUT4 translocation.	diosmetin	36-40	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	177-182
34086130-0	2021	Correction to: Diosmetin induces apoptosis in ovarian cancer cells by activating reactive oxygen species and inhibiting the Nrf2 pathway.	diosmetin	15-24	NFE2 like bZIP transcription factor 2	Homo sapiens	124-128
35191607-0	2022	Diosmetin alleviates cerebral ischemia-reperfusion injury through Keap1-mediated Nrf2/ARE signaling pathway activation and NLRP3 inflammasome inhibition.	diosmetin	0-9	Kelch-like ECH-associated protein 1	Rattus norvegicus	66-71
35191607-0	2022	Diosmetin alleviates cerebral ischemia-reperfusion injury through Keap1-mediated Nrf2/ARE signaling pathway activation and NLRP3 inflammasome inhibition.	diosmetin	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	81-85
35191607-0	2022	Diosmetin alleviates cerebral ischemia-reperfusion injury through Keap1-mediated Nrf2/ARE signaling pathway activation and NLRP3 inflammasome inhibition.	diosmetin	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	123-128
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	Kelch-like ECH-associated protein 1	Rattus norvegicus	53-88
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	Kelch-like ECH-associated protein 1	Rattus norvegicus	90-95
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	NFE2 like bZIP transcription factor 2	Rattus norvegicus	125-159
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	NFE2 like bZIP transcription factor 2	Rattus norvegicus	161-165
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	heme oxygenase 1	Rattus norvegicus	262-278
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	heme oxygenase 1	Rattus norvegicus	280-284
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	290-323
35191607-4	2022	Then our results showed that diosmetin downregulated kelch like ECH-associated protein 1 (Keap1) expression, and upregulated nuclear factor E2-related factor 2 (Nrf2) expression, antioxidant response element (ARE) activity and the mRNA and protein expression of heme oxygenase 1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1).	diosmetin	29-38	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	325-329
35191607-5	2022	Keap1 overexpression or Nrf2 silencing both attenuated the neuroprotective effect of diosmetin on PC12 cells.	diosmetin	85-94	Kelch-like ECH-associated protein 1	Rattus norvegicus	0-5
35191607-5	2022	Keap1 overexpression or Nrf2 silencing both attenuated the neuroprotective effect of diosmetin on PC12 cells.	diosmetin	85-94	NFE2 like bZIP transcription factor 2	Rattus norvegicus	24-28
35191607-6	2022	Moreover, diosmetin inhibited the levels of nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin domain containing 3 (NLRP3) inflammasome pathway related proteins and inflammatory cytokines interleukin (IL)-1beta and IL-18.	diosmetin	10-19	C-X-C motif chemokine receptor 5	Rattus norvegicus	107-110
35191607-6	2022	Moreover, diosmetin inhibited the levels of nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin domain containing 3 (NLRP3) inflammasome pathway related proteins and inflammatory cytokines interleukin (IL)-1beta and IL-18.	diosmetin	10-19	NLR family, pyrin domain containing 3	Rattus norvegicus	139-144
35191607-6	2022	Moreover, diosmetin inhibited the levels of nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin domain containing 3 (NLRP3) inflammasome pathway related proteins and inflammatory cytokines interleukin (IL)-1beta and IL-18.	diosmetin	10-19	interleukin 1 alpha	Rattus norvegicus	211-233
35191607-6	2022	Moreover, diosmetin inhibited the levels of nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin domain containing 3 (NLRP3) inflammasome pathway related proteins and inflammatory cytokines interleukin (IL)-1beta and IL-18.	diosmetin	10-19	interleukin 18	Rattus norvegicus	238-243
35191607-9	2022	In conclusion, diosmetin attenuated OGD/R-induced PC12 cell viability inhibition, apoptosis, oxidative stress and inflammation through Keap1-mediated Nrf2/ARE signaling activation and NLRP3 inflammasome inhibition, and alleviated CIR-induced neurological injury in MCAO rat model.	diosmetin	15-24	Kelch-like ECH-associated protein 1	Rattus norvegicus	135-140
35191607-9	2022	In conclusion, diosmetin attenuated OGD/R-induced PC12 cell viability inhibition, apoptosis, oxidative stress and inflammation through Keap1-mediated Nrf2/ARE signaling activation and NLRP3 inflammasome inhibition, and alleviated CIR-induced neurological injury in MCAO rat model.	diosmetin	15-24	NFE2 like bZIP transcription factor 2	Rattus norvegicus	150-154
35191607-9	2022	In conclusion, diosmetin attenuated OGD/R-induced PC12 cell viability inhibition, apoptosis, oxidative stress and inflammation through Keap1-mediated Nrf2/ARE signaling activation and NLRP3 inflammasome inhibition, and alleviated CIR-induced neurological injury in MCAO rat model.	diosmetin	15-24	NLR family, pyrin domain containing 3	Rattus norvegicus	184-189